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Abstract 
 
Human hepatic lipase (hHL) is bound to the cell surface via heparan sulfate proteoglycans 
(HPSGs) and hydrolyzes triglycerides and phospholipids within circulating lipoproteins. 
High-density lipoprotein (HDL) transports excess extrahepatic cholesterol to the liver for 
excretion. However, small lipid-deficient HDL generated by hHL action has the ability to 
accept more cholesterol. I hypothesized that a peptide mimicking the cell surface 
associations of hHL will displace hHL from cell surfaces, increasing its activity in cell 
culture media. To test this hypothesis, I have recombinantly expressed and purified a 
tagged mimetic peptide, encompassing the major heparin-binding domain of hHL. Results 
from in vitro lipase displacement assays showed that the peptide has an ability to displace 
active HPSG associated lipases. Data from proton nuclear magnetic resonance experiments 
showed that structural changes occur in the peptide in the presence of heparin. Overall, 
these data provide a foundation to use mimetic peptides for the displacement of cell 
surface associated lipases. 
.  
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Chapter 1: Introduction 
 
1.1 Overview 
 
  
 By definition, cardiovascular disease (CVD) is any disease or injury that affects 
the heart and/or circulation; this includes coronary heart disease, stroke, and coronary 
artery disease (or atherosclerosis). CVD has the highest mortality for any non-
communicable disease worldwide, accounting for 17.5 million deaths in 2008.1 In 
Canada, CVD accounted for 74,255 deaths in 2003, accompanied with an economic 
burden of 18.5 billion dollars.2,3 In 2005, it was estimated that Canada spent 96 million 
dollars towards funding CVD research.4 The general causes of CVD are correctable 
lifestyle choices that include tobacco use, physical inactivity, diet, and excess alcohol use. 
However, lifestyle habits are not the whole story. Hereditary elements can also contribute 
greatly to the development of CVD and especially premature death of individuals 
suffering with the disease. Considering the huge socioeconomic impact CVD has world 
wide, current research is focused on developing new approaches to treat and prevent 
CVD. Since one of the risk factors of CVD is the imbalance of cholesterol within the 
body, understanding how cholesterol is synthesized, metabolized, stored, and removed 
from the body is important for developing new treatments. The removal of excess 
cholesterol from peripheral tissues for bile excretion is achieved by a multi-step process 
known as reverse cholesterol transport (RCT).5-7 This anti-atherogenic process is 
accomplished with the help of numerous proteins, some which are also important in 
lipoprotein metabolism. 
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1.1.1 Atherosclerosis 
 
 Atherosclerosis is one of the major underlying causes of severe health problems, 
such as coronary heart disease and stroke. It is defined by the hardening of the arteries 
due to cholesterol accumulation within the intima of the artery.8 The progression of 
atherosclerosis results from the interplay of various molecular events that usually go 
undetected until a clinical event occurs, such as a myocardial infarction. Both researchers 
and physicians have been interested in understanding the clinical and molecular factors 
that contribute to the development of atherosclerosis. Considering that cholesterol 
accumulation plays an integral part in the progression of atherosclerosis, researchers have 
been particularly motivated to fully understand the role that cholesterol metabolism plays 
in atherosclerosis. Research thus far has been able to chronologically elucidate the events 
of atherosclerosis, however, the progression of some of these events still remains unclear. 
 One of the first events of arterial thickening is the appearance of fatty streaks on 
the inner surface of the artery. They are inert and do not impede blood flow. Fatty streaks 
appear yellow-white in colour due to the accumulation of cholesterol-loaded 
macrophages. These cholesterol-loaded macrophages have a foamy appearance and are 
aptly referred to as foam cells. The cholesterol that accumulates within foam cells is 
carried by low-density lipoproteins (LDL), which is commonly termed “bad cholesterol”. 
LDL is given this name because it functions to carry cholesterol from the liver to 
peripheral tissues. This is why elevated LDL is considered a risk factor for CVD.9 
Increased LDL within the circulation increases the chances of LDL penetrating into the 
artery intima and developing into a fatty streak. How these fatty streaks mature into 
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atherosclerotic plaques remains to be fully elucidated. Maturation is believed to involve a 
complex interplay between oxidative stress, pro-inflammatory cytokines, and the 
infiltration of oxidized LDL (oxLDL). Theories suggest that in order for LDL to penetrate 
the intima of the artery, a process known as endothelial activation must occur.8 During 
this process, LDL penetrates the endothelium and is retained within the intima of the 
artery where it can be oxidized. The oxLDL initiates the expression of adhesion 
molecules on the surface of the artery, allowing circulating monocytes to adhere, 
penetrate the endothelium, and enter the intima. Once inside the intima, the intruding 
monocytes differentiate into macrophages and start to accumulate oxLDL. The increased 
accumulation of oxLDL within macrophages positively fuels the process for more 
monocytes to enter the intima. When the macrophage accumulates oxLDL, it is then 
termed a foam cell. This differentiation is an essential step for the progression of 
atherosclerosis.10 It is the build up of lipid-laden foam cells that start to form fatty streaks 
and eventually mature into atherosclerotic plaques. The progression from fatty streak to 
plaque is believed to occur when smooth muscle cells penetrate the endothelium and 
accumulate within the intima.8 Once the plaque has grown beyond the capacity of the 
intima, it encroaches on the arterial lumen and affects blood flow. Often a growing plaque 
is fragile, increasing its chance of rupture. If a plaque ruptures, the contents come into 
contact with blood coagulation factors, creating a thrombus that obstructs blood flow 
(Figure 1). This increases the risk of serious health problems such as myocardial 
infarction or stroke.  
 
	   	   	  4	  
 
 
 
 
 
 
 
 
 
  
Figure 1: Schematic depiction of the progression of atherosclerosis  
Increased LDL within the circulation increases the incidence of LDL penetrate the 
vascular endothelium and entry to the intima. Once inside the intima, the LDL can be 
oxidized, forming oxLDL. The oxLDL increases the expression of adhesion molecules 
on the endothelium, attracting circulating monocytes. The monocytes can enter the 
intima where they can accumulate oxLDL, thus differentiating the monocytes into 
macrophages and eventually foam cells. As the foam cells start to accumulate and 
expand within the intima, the lamina is weakened, allowing smooth muscle cells to 
infiltrate the intima and increase plaque growth. When the plaque outgrows the 
limitations of the intima it ruptures, resulting in thrombosis, leading to a cardiac event. 
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Figure 1 
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1.1.2 Lipoproteins: structure, function, and metabolism 
 
 Considering cholesterol is a major player in the progression of atherosclerosis, it 
is very important to study and understand its means of transportation throughout the body. 
Cholesterol is amphipathic, meaning it has both “water loving” and “water hating” 
properties and is not completely soluble in the aqueous environment of the blood stream. 
The body deals with this problem by packing cholesterol within lipoprotein molecules, 
shielding the “water hating” portion of cholesterol from the hydrophilic environment of 
the circulation.11 However, cholesterol is not the only molecule that is packed and 
transported by lipoproteins. Hydrophobic lipids, such as triglycerides (TG), are 
completely “water hating” and are entirely insoluble within the bloodstream; this is why 
lipids require a special means of transport within the circulation. Lipoproteins contain 
both lipid and protein moieties, with their function being dependent upon both. 
Lipoproteins are also classified by their densities (Figure 2). The protein moieties 
associated with a lipoprotein can aid in the scaffolding of the lipoprotein molecule, act as 
cofactors for enzymes, and act as ligands for cell surface receptors.  
 All lipoproteins have the same basic structure: a hydrophobic core containing TG 
and cholesteryl esters (CE) that is surrounded by an amphipathic monolayer of 
phospholipids (PL) with embedded apolipoproteins and cholesterol. Lipoproteins require 
apolipoproteins for two crucial functions in the lipidation and catabolism of lipoprotein 
molecules. The first major function is to act as a structural scaffold, which shapes and 
holds the lipoprotein together, thus shielding the hydrophobic core from the bloodstream. 
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Figure 2: The classes of lipoproteins 
There are 5 classes of lipoproteins that are characterized by their density obtained by 
density gradient ultracentrifugation analysis.12 The classes are high-density lipoprotein 
(HDL), intermediate-density lipoprotein (IDL), low-density lipoprotein (LDL), very-
low density lipoprotein (VLDL) and the least dense called chylomicron. The diameters 
of lipoproteins are inversely proportional to their densities. For example, chylomicrons 
have the largest diameter but have the lowest density. The density range for each 
lipoprotein class is given next to the diagram for each. The percentage of total lipid 
and protein associated with each class are also indicated. (Figure reproduced from 
reference 12 with permission).  
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Figure 2 
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The second major function is to act as a receptor for lipoprotein uptake via receptor-
mediated endocytosis in various tissues. The apolipoproteins associated with lipoproteins 
differ among the lipoprotein classes. For example, apolipoprotein (apo) A-I and apoA-II 
are primarily found embedded on the monolayer of high-density lipoprotein (HDL) 
molecules, while apoB is primarily found on very-low density lipoproteins (VLDL) and 
LDL. 
 When a meal is ingested, the dietary TG and PL pass through the stomach and 
enter the small intestine where they are hydrolyzed by human pancreatic lipase (hPL), 
generating free fatty acids. The free fatty acids cross the brush border membrane of the 
intestine and enter the enterocytes.13,14 Once inside, the free fatty acids are trafficked 
through the endoplasmic reticulum.15 These are then combined with CE and apoB-48 to 
form chylomicrons (CM). The CMs pass through the lymphatic capillaries and enter the 
vascular circulation via the thoracic duct. Once within the circulation, the CMs transport 
TGs to various tissues to be used for lipid storage or oxidation. The TG components of 
CMs are hydrolyzed by human lipoprotein lipase (hLPL), creating smaller, more dense 
CMs, termed CM remnants.16 These CM remnants are taken up by the liver, allowing for 
its protein and lipid cargo to be used for intracellular functions, such as VLDL 
synthesis.16 The liver synthesizes and secretes VLDL, which functions similarly to CM to 
transport endogenous lipids within the circulation. As VLDL travels throughout the 
circulation, it encounters hLPL on epithelial cell surfaces, which acts to cleave the acyl 
esters of the TG components of VLDL. This hydrolysis results in the de-lipidation of the 
molecule, creating a more dense VLDL particle that is classified as intermediate-density 
	   	   	  10	  
lipoprotein (IDL). IDL molecules can have two fates: they can either continue to circulate 
within the bloodstream, or they can be taken up by the liver via receptor-mediated 
endocytosis. If IDL continues to circulate within the bloodstream, it can be further 
hydrolyzed to produce the cholesterol-rich lipoprotein LDL. LDL functions to transport 
cholesterol to peripheral tissues where the cholesterol is either metabolized or stored. 
Considering this function of LDL, it is well accepted to be pro-atherogenic in nature, as it 
transports cholesterol from the liver and deposits it in the peripheral tissues. In an attempt 
to keep the cholesterol levels in balance, HDL functions to transport cholesterol from 
peripheral tissues back to the liver, where it can be excreted in bile. HDL is synthesized 
both by the liver and the intestines to contribute to the HDL pool within the 
bloodstream.17,18 HDL is considered anti-atherogenic due to the role it plays in the 
process of RCT by moving cholesterol from the peripheral tissues to the liver for 
excretion.6 
 HDL can be classified into α and preβ molecules, based upon their electrophoretic 
mobility on an agarose gel.16 This classification is due to variations in the lipid and 
apolipoprotein content of HDL. Preβ-HDL molecules are lipid deficient and α-HDL are 
lipid rich.19 Due to the low amount of lipid and the high amount of apoA-I, preβ-HDL is a 
very potent cholesterol acceptor.20 HDL can carry anywhere from one to four apoA-I 
molecules, accounting for roughly 65% of the protein mass in HDL.21,22 ApoA-I has a 
structure which consists of a single polypeptide chain with stretches of amphipathic α-
helices.23 The hydrophobic face of the polypeptide is embedded into the lipid surface of 
the lipoprotein. ApoA-I is secreted from both the liver and intestines as a lipid-deficient 
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protein with a squat and oblate spheroid structure. The squat structure matures into a 
more open extended conformation as the apoA-I moiety is covalently lipidated.23 
However, the intestines and liver are not the only source of lipid deficient apoA-I, as it 
can also be liberated from lipoproteins as they are hydrolyzed in the bloodstream, 
producing lipid-deficient preβ-HDL.24 Lipids are loaded onto apoA-I by the adenosine-
triphosphate binding cassette transporter A1 (ABCA1).25 ABCA1 is a transmembrane 
protein and it functions to control the traffic of cholesterol and PL from inside a cell to a 
cholesterol acceptor, located outside the cell, such as apoA-I.  
ApoA-I has also been observed to have some beneficial anti-inflammatory 
properties, which may be effective for reducing inflammation associated with 
atherosclerosis.26 Rabbits with collar induced atherosclerosis and that were treated with 
HDL, had an increased ratio of smooth muscle cells to macrophages compared to 
untreated rabbits.27 A reduction in atherosclerotic plaque size was also observed in 
cholesterol-fed, atherosclerotic rabbits when they were treated with HDL.28 This study 
also observed that the reduction in plaque size was comparable to animals treated with a 
common statin, atorvastatin. This provides further evidence that raising preβ-HDL within 
the circulation could be an effective therapy against atherosclerosis. 
 
1.1.3 Reverse cholesterol transport 
  
 Human hepatic lipase (hHL) is an extracellular enzyme that cleaves the sn-1 acyl 
esters of TGs and PLs within circulating lipoprotein molecules.29 The hydrolysis of TG 
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and PL in HDL by hHL produces smaller, lipid deficient HDL molecules.30 It has been 
proposed that HDL promotes the transfer of cholesterol from peripheral tissues back to 
the liver for excretion.31 As HDL molecules are metabolized within the circulation, the 
density of HDL increases and their lipid composition is altered. (See section 1.1.4 for 
more about cholesteryl ester transfer protein (CETP)). A form of HDL known as preβ-
HDL can be generated during HDL metabolism via the displacement of its major protein 
component, apoA-I.32 It is the most dense form of HDL and it is the most lipid deficient. 
Considering preβ-HDL’s lipid deficiency, it has the capacity to accept more cholesterol 
than its lipid-laden HDL counterparts in vitro.33 This may allow preβ-HDL molecules to 
transport more cholesterol back to the liver for excretion in the bile.34 Due to its 
cholesterol accepting nature, increasing the concentration of preβ-HDL molecules within 
the circulation is an appealing treatment strategy to combat CVD. One way to increase 
preβ-HDL molecules within the circulation is to increase the hydrolysis function of hHL, 
thus generating more cholesterol accepting preβ-HDL molecules. An increase of hHL 
activity within the circulation could provide a promising anti-atherogenic therapy for 
reducing the risk of CVD, through the increased generation of preβ-HDL molecules and 
excretion of excess cholesterol via RCT (Figure 3). 
 There are two ways in which cholesterol can be transported in the bloodstream: 
forward transport and reverse transport. Forward transport describes the movement of 
cholesterol from the liver to peripheral tissues. This is usually carried out by TG rich 
lipoproteins and is a process that is recognized as pro-atherogenic. Reverse transport of 
cholesterol is the movement of cholesterol from the peripheral tissues to the liver where it  
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Figure 3: Schematic of reverse cholesterol transport 
Preβ-HDL, a lipid deficient molecule, has the propensity to accept cholesterol from 
extra-hepatic tissues through the process of cholesterol efflux. As preβ-HDL travels 
through the bloodstream, it can accumulate more cholesterol, TG and PL, and 
consequently develops into a mature HDL molecule. Cell surface associated hHL will 
cleave the acyl esters of the TG and PL at the site of the liver. The liver will selectively 
uptake the cholesteryl esters (CE) and ultimately excrete the cholesterol through the 
bile. To complete the process of reverse cholesterol transport, the apoA-I moiety of the 
HDL molecule can be recycled back to preβ-HDL, thus continuing the process of 
removing cholesterol from the peripheral tissues and taking it back to the liver for 
excretion. 
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Figure 3 
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can ultimately be excreted. The pioneers of RCT, Glomset and Wright, have defined RCT 
as the overall flux of cholesterol from the entire periphery to the liver and then finally 
being excreted.5 They have also proposed that the esterification of cholesterol in 
lipoproteins would drive the net efflux of cholesterol and “trap” the HDL bound 
cholesterol, preventing the exchange of the cholesterol from HDL back to the cells. 
The complex process of RCT can be broken down into four critical steps: 1) free 
cholesterol is effluxed to HDL from the extra hepatic cells;35 2) free cholesterol is 
esterified by the enzyme lecithin-cholesterol acyltransferase (LCAT);5 3) the cholesterol 
is receptor-mediated endocytosed by the liver via the scavenger receptor B type I (SR-
BI);36 and 4) HDL is remodelled by hHL,30 and the apoA-I moiety may reinitiate the 
process of continuing to remove cholesterol from the peripheral tissues.37 The first step in 
RCT is to efflux the cholesterol to the cholesterol acceptor, apoA-I, via ABCA1. The 
binding also decreases the degradation of apoA-I.38 These studies also suggest that 
increasing preβ-HDL within the circulation could potentially increase cholesterol efflux. 
 As cholesterol and PL are effluxed to the circulating apoA-I molecule, it becomes 
more enriched in lipid and continues to accumulate more PL and cholesterol. As it 
continues to circulate through the bloodstream collecting more PL and cholesterol, preβ-
HDL is converted into a mature α-HDL molecule. The free cholesterol is converted by 
LCAT to the less toxic esterified cholesterol that is then stored within the hydrophobic 
core of HDL.36 When the mature HDL reaches the liver, the surface-bound hHL 
hydrolyzes the TG and PL, thus altering the lipid content of HDL.39 This alteration of the 
lipid content promotes the dissociation of apoA-I from the HDL molecule, allowing it to 
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reinitiate the process of RCT. The liver takes up the lipids released from HDL via SR-BI. 
The CEs are converted back into cholesterol and ultimately excreted with the bile.36  
 Another important cholesterol transporter is adenosine-triphosphate cassette 
binding transporter G1 (ABCG1). It is similar to ABCA1, however, it preferentially 
effluxes cholesterol to mature α-HDL particles. ABCG1 increases the unesterified 
cholesterol in the plasma membrane where it can be readily effluxed to the HDL 
particles.40 Both ABCA1 and ABCG1 are under the transcriptional control of the liver-X-
receptor (LXR).41,42 In vivo, LXR is activated by oxidized cholesterol within cholesterol 
loaded foam cells,43 which increases the expression of transporters in the plasma 
membrane that will in turn increase the efflux of cholesterol to apoA-I or preβ-HDL.38,40 
Double-knockout studies of ABCA1 and ABCG1 transporters in macrophages have 
shown a reduction in the efflux of cholesterol and lipid accumulation within 
macrophages.44 These findings provided evidence of the importance of these transporters 
in cholesterol efflux and the overall process of RCT. 
 
1.1.4 HDL functionality 
 
 Researchers and physicians have understood for quite some time that the risk for 
CVD is inversely proportional to the circulating levels of HDL cholesterol (HDL-C).45 
This is due to the anti-atherogenic function of HDL: raising your levels of HDL would 
increase RCT and reduce your risk of CVD. However, over the past few years this 
understanding has been changing. Many studies have investigated whether increasing 
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HDL within the circulation will result in an increase of RCT; however, the results show 
that it is not the amount of HDL-C, but actually the functionality of the HDL molecule 
itself that is of importance in CVD protection.46 
Studies were performed to increase the expression of ABCA1 and ABCG1 by 
using an agonist for the upstream regulator LXR to potentially increase the amount of 
cholesterol that is effluxed to HDL, thereby increasing RCT.47 These studies reported 
increased HDL levels in agonist-treated LDL receptor knockout mice, along with 
increased cholesterol efflux to the HDL molecules. 
 The elevation of HDL-C within the circulation with a potent HDL-raising drug, 
niacin, initially showed great promise. Niacin has been shown in small clinical trials to 
increase HDL-C levels up to 25%.48 However, when niacin was tested in larger and 
longer clinical trials, there was an absence of improved CVD outcomes despite elevated 
HDL-C, thus the studies were subsequently terminated.49 
Another therapeutic strategy to raise HDL was through the use of CETP inhibitors 
that function to retain cholesterol in HDL and prevent the transfer of cholesterol to pro-
atherogenic lipoproteins. The use of CETP inhibitors stem from the observation that the 
transgenic expression of the CETP gene stimulated the development of severe 
atherosclerosis in mice.50 Clinical trials with torcetrapib, a CETP inhibitor, showed an 
increased incidence of CVD events with a 1.25 hazard ratio, despite an increase of HDL-
C by 72% and the lowering of LDL cholesterol by 25%.51 Thus, the inhibition of CETP 
raised concerns about the ability to produce functional HDL molecules. These studies 
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provide further evidence of the importance of the functionality of the HDL molecule and 
not just the arbitrary raising of HDL-C amount. 
 What does show more promise than raising HDL-C levels is to instead raise 
apoA-I levels via infusions of reconstituted apoA-I from human plasma.52 In animal 
studies, increasing apoA-I, the protein component needed to synthesize preβ-HDL, 
increases RCT.53 In addition to studies with full-length apoA-I, apoA-I mimetic peptides 
have been tested and shown to also to increase in the amount of cholesterol that is also 
effluxed.54 These studies suggest that cholesterol efflux is dependent on the functionality 
of the HDL molecule and its ability to accept cholesterol.  
 
1.1.5 Human hepatic lipase and its role in atherosclerosis 
 
 hHL is an extracellular enzyme bound to the cell surface via heparan sulfate 
proteoglycans (HSPG).55 It functions to hydrolyze the sn-1 acyl esters of TG and PL 
within circulating lipoprotein molecules.29 Considering its lipase function, hHL is very 
important in maintaining normal levels of lipoproteins within the circulation. However, 
its role in atherosclerosis is very controversial: there are arguments supporting that hHL 
play both a pro-atherogenic and an anti-atherogenic role.  
Patients who are deficient in hHL exhibit increased TG content of VLDL and 
IDL.56 Patients with hHL deficiency have also been observed to have higher levels of TG 
enriched HDL2, a subfraction of HDL.57 These studies indicate that hHL deficiency could 
result in an increased risk of an individual developing atherosclerosis. Animal studies also 
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have conflicting results on the role of HL in atherosclerosis. Barcat et al. had also 
confirmed that HL deficiency leads to development of atherosclerosis, using a mouse 
model lacking both HL and the LDL receptor.58 The LDL receptor knockout model is a 
well-accepted atherosclerosis model.59 Mice lacking both HL and the LDL receptor 
showed an increase in plasma TG rich lipoproteins with a reduction in liver uptake of 
remnants, as well as premature aortic lesions resulting in atherosclerosis.58 
Other studies indicating that hHL is anti-atherogenic involve the increase in 
activity of hHL within the circulation. Fan et al. observed that rabbits overexpressing 
hHL have a 5-fold-decrease in plasma cholesterol with a reduction in the large TG-rich 
HDL particles, as well as IDL particles.60 This indicates that hHL is important in the 
reduction of plasma cholesterol. Busch et al. observed similar findings: transgenic mice 
overexpressing hHL had a 34% decrease in HDL-C when compared to the control 
animals and a decrease in the size of the HDL particles.61 They also observed a decrease 
in aortic cholesterol content in these mice. These studies provide evidence of the anti-
atherogenic properties of hHL and the potential advantages to increasing its activity 
within the circulation.  
 Conversely, there are studies that provide evidence that hepatic lipase (HL) is pro-
atherogenic.62-64 Nong et al. studied two independent atherogenic mouse models, an 
apoE-deficient and a LCAT transgenic.62 They observed that LCAT transgenic mice 
deficient in HL had increased plasma concentrations of apoB containing lipoproteins. 
However, despite this elevation in pro-atherogenic lipoproteins, the animals had a 
reduced risk of diet-induced atherosclerosis. Furthermore, in both the LCAT transgenic 
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and apoE-deficient models, they demonstrated that HL produced by macrophages 
increased aortic lesion formation and the absence of HL was observed to lower aortic 
lesion formation. This suggests that HL is involved in the progression of atherosclerosis 
in a manner that in independent of its role in lipoprotein metabolism. In support of these 
studies, a double knockout mouse model for apoE and HL exhibited increased plasma 
cholesterol accompanied with an unexpected reduction in atherosclerotic lesions.65  
 
1.1.6 Human hepatic lipase structure 
 
 Secreted hHL is comprised of 476 amino acids with a molecular mass varying 
from 55-69 kDa, depending upon the degree of glycosylation on its four N-linked 
glycosylation sites.66 Of the four glycosylation sites, asparagine-56 is crucial for the 
successful secretion and activity of hHL.67 hHL is a member of the sn-1 specific 
subfamily of the lipase superfamily. This subfamily includes the closely related lipases 
hLPL, human endothelial lipase (hEL), and hPL. The percent identities between the 
members of the lipase family are listed in Table 1. To summarize, hLPL and hEL share 
48.1% sequence identity, while hLPL and hHL share 45.7% sequence identity. However, 
hHL, hLPL, and hEL only share roughly 30% sequence identity with hPL. Considering 
their variations in conserved sequences, they still all share a characteristic catalytic triad 
(serine-aspartic acid-histidine) and a lipase consensus sequence (glycine-Xaa-serine-Xaa- 
glycine) which is conserved within the majority of lipases (Figure 4).68 No portion of the 
hHL structure has been determined. However, sequence homology with the solved  
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Figure 4: Sequence alignment of the lipase family 
The amino acid sequences of the human sn-1 lipase family are aligned. The alignment 
also includes mHL for comparison of the heparin binding domains with hHL. The 
amino acids are numbered according to the secreted protein sequence. The red box 
indicates the lipase consensus sequence. The blue box highlights a partial portion of 
the C-terminal that houses the major heparin-binding domain for hHL. When mHL and 
hHL C-termini are compared, there is a lack of conserved residues, specifically the 5 
(KRKIR) basic residues of hHL, which accounts for the difference in cell surface 
binding between the two HL species. Highlighted in green within the distal N-terminal 
of hHL is another putative HBD (R310, K312, K314, R315).74 The red line preceding 
the putative N-terminal HBD is the hinge region of hHL that dissects the N- and C- 
terminals.72 Denoted by the black triangles are the 8 conserved cysteine residues. The 
N-linked glycosylation sites are highlighted in yellow, with asparagine-56 in orange. 
The lysine-aspartic acid-histidine catalytic triad is denoted with a pentagon overhead. 
The lid domain is denoted with a light blue box. The legend for the alignment is as 
follows: (*) fully conserved residue, (:) residues with strong similar properties, (.) 
residues with weak similar properties. 
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Table 1: Sequence similarity between members of the lipase family 
 
The amino acids sequences of the lipase family were aligned using Clustal Omega 
software69 (Figure 4) with the following accession numbers: hHL: NP_000227.2, mHL: 
NP_032306.2, hPL: CAA4691.1, hLPL: NP_000228.1, hEL: NP_006024.1. The numbers 
in the table are represented of the percent homology between the different members of the 
sn-1 lipase family. 
 
 
 
 
 
 
 
 
 
	   hPL	   hHL	   mHL	   hLPL	   hEL	  hPL	   100.00	   31.85	   31.24	   31.48	   31.93	  hHL	   31.85	   100.00	   75.63	   45.70	   42.49	  mHL	   31.24	   75.63	   100.00	   46.17	   43.76	  hLPL	   31.48	   45.70	   46.17	   100.00	   48.08	  hEL	   31.93	   42.49	   43.76	   48.08	   100.00	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structure of hPL provides some information about certain domains of hHL. hPL has been 
described as having a two-domain structure: the amino (N)-terminal domain has a 
globular structure and contains the active site, and the carboxyl (C)-terminal domain 
consists of β-sheets.70 Like hPL, the active site for hHL is understood to be located in the 
N-terminal domain. The C-terminal domain of hHL has been characterized to hold the 
major heparin-binding site, as well as the main lipoprotein binding site.71,72 This has been 
observed experimentally using peptide array assays to characterize the heparin binding 
ability of the C-terminal.73,74 The heparin-binding domain (HBD) of hHL contains 
positively charged amino acids, which interact electrostatically with the negatively 
charged HSPG on the cell surface. The putative HBD of hHL was determined to reside 
within the last 70 amino acids of the hHL sequence, with the last five amino acids 
contributing greatly to heparin binding.75 To provide further evidence of the location of 
the major HBD, when the sequences of mouse HL (mHL) and hHL are aligned, the 
mouse sequence is missing the last five (KRKIR) positively charged amino acids. This 
has been confirmed experimentally: mHL is observed to have a low affinity for heparin-
sepharose, eluting with 0.4 M NaCl, when compared to full-length hHL, which elutes 
from heparin-sepharose with 0.7 M NaCl.73 In agreement with the heparin-binding 
results, the activity of hHL within circulation increases 1,500 fold following its 
displacement from the cell surface HSPGs by heparin.76 
 hHL is thought to be catalytically active as a homodimer.73 This is experimentally 
supported by the purification of hHL via size-exclusion chromatography. The eluted 
protein peak containing lipase activity has a calculated molecular mass of 107 kDa, in 
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agreement with the theoretical mass for an hHL dimer (106.8 kDa). To provide further 
evidence that active hHL exists as a dimer, when it is rendered inactive, the eluted protein 
fraction has a molecular mass is 63 kDa.73  
 
1.1.7 Post-translational regulation of human hepatic lipase 
  
 The regulation of HL remains to be fully elucidated. It has been known for quite  
some time that the activity of hHL in the bloodstream increases after it is displaced from 
the cell surface via heparin.76 It is proposed that there are two inactive pools of hHL: one 
is the HSPG bound enzyme and the other is the hHL bound to lipoproteins within the 
circulation.77 In agreement with these proposals, Ramsamy et al. demonstrated that cell 
surface bound hHL is inactive.78 However, there are studies which suggest that some 
lipases, specifically hLPL, is catalytically active when still bound to the cell surface via 
HSPG, and this association of hLPL with the HSPG actually enhances its activity.79 
Current findings suggest that the activity of hHL is dependent on its displacement from 
cell surfaces by its binding partner, HDL.80,81 It has been known for some time that apoA-
I and HDL are able to displace hHL from cell surface HSPG and that the association of 
hHL with these molecules modulates hHL activity.78 These studies suggest that the 
activity of hHL is closely correlated with its ability to displace hHL from cell surface 
HSPGs. The liberation of hHL by HDL within the circulation enables hHL to gain access 
to its circulating substrates. HDL isolated from normolipidemic females has been shown 
to contain a significant amount of hHL mass compared to their male counterparts. This 
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may be responsible for the reduced magnitude of postprandial lipidemia, which is 
observed in women compared to men.82 This may also increase the remodelling of 
HDL,77 which could increase the RCT process. All of these studies suggest that 
increasing the displacement of hHL from cell surfaces is a promising approach to 
increasing the clearance of both cholesterol and TG from the bloodstream. 
 
1.2 Objectives and Hypothesis 
 
1.2.1 Objectives 
 
 The objective of this research is to investigate the HBD of hHL, and to use a 
mimetic peptide that is analogous to the C-terminal sequence of hHL to displace hHL 
from cell surfaces. This increase in activity will enhance the remodelling of HDL to 
create preβ-HDL: a more potent cholesterol acceptor that will increase the cholesterol 
efflux to these particles. This will potentially increase the overall process of RCT. The 
first part of this project deals with the functional analysis of the peptide and its ability to 
displace hHL from the cell surface. The second aspect of this project is to conduct a 
structural analysis of the peptide, hHL442-476, to gain novel information about the structure 
of the HBD of hHL and to characterize the interaction between the peptide and heparin.  
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1.2.2 Hypothesis 
 
 I hypothesize that an hHL-derived peptide, which mimics the cell surface 
association of hHL, will be able to displace hHL from cell surfaces, in turn increasing 
free hHL activity upon displacement. This in turn will potentially increase cholesterol 
efflux to HDL and possibly increase the overall process of RCT.  
 
1.3 Summary 
 
 CVD is the leading cause of mortality in the Western world.1,83 Many therapies 
have attempted to reduce one’s risk of CVD. However, many therapies have serious side 
effects or fail to reduce CVD in a large population. By conducting an investigation of a 
mimetic hHL peptide, we hope to provide a novel avenue in the world of cholesterol 
lowering agents. By carrying out both functional and structural studies, we hope to 
provide evidence using a mimetic peptide to displace hHL from cell surfaces. These 
studies will hopefully be the basis of a new peptide drug and therefore help combat the 
progression of atherosclerosis. 
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Chapter 2: Materials and Methods 
 
2.1 Generation of the hHL442-476 Peptide 
 
2.1.1 Generation of the phHL442-476 plasmid 
 
 The mimetic hHL protein construct was designed to be a thioredoxin (Trx) fusion 
protein containing a hexahistidine (6xhis)-tag for purification and immunoblot 
identification, an S-tag for immunoblot identification, and the hHL sequence containing 
the major HBD, specifically amino acids 442-476 (hHL442-476)75 (Figures 5 and S1). The 
last 26 amino acids within the 442-476 sequence of hHL contains clusters of positively 
charged amino acids that align with previously elucidated heparin binding motifs (Figure 
5B). This HBD is absent in mHL, and is replaced with either neutral or negatively 
charged amino acids, resulting in mHL having a lower affinity for cell surface HSPGs 
compared to hHL.75 The basic amino acids in hHL responsible for heparin binding are 
highlighted in red, while the analogous amino acids of mHL are highlighted in green. The 
basic amino acids within the HBD of hHL also align with previously elucidated heparin 
binding motifs.84,85 The hHL442-476 sequence also contains two cysteine residues and could 
form a putative disulfide bridge.  
 The nucleotide sequence corresponding to the 442-476 amino acid sequence was 
amplified by polymerase chain reaction (PCR) with primers that incorporated BamHI  
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Figure 5: Schematic of the hHL442-476-Trx protein 
A) Schematic of the hHL442-476-Trx and the Trx protein constructs. Both constructs 
contain the Trx protein, plus 6xhis- and S-tags that are located within the region 
between the Trx protein and the hHL442-476 sequence. There are also two cleavage 
sites: one for enterokinase (E) and one for thrombin (T), as indicated by the dashed 
lines. The constructs also contain a 7 amino acid linker region (AMADIGS), which 
links the hHL442-476 sequence to the Trx protein. The Trx construct contains no hHL 
sequence and thus it was used as a vector control that produced a protein with a 
molecular mass of 21 kDa. The hHL442-476-Trx construct contains the Trx protein 
linked to the hHL C-terminal sequence containing amino acids 442-476, having a 
molecular mass of 23 kDa.  B) The hHL442-476 sequence, aligned with the analogous 
sequence of mHL, shows the difference in the amino acid composition of the C-
termini of the two proteins. The basic amino acids present in the hHL442-476 sequence 
are arranged in patterns that align with previously elucidated heparin binding 
motifs.84,85 B represents a basic amino acid and x is any amino acids. Also highlighted 
in blue is the putative disulfide bridge located within the hHL442-476 sequence. 
	   	   	  30	  
Figure 5 
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and HindIII restriction endonuclease sites into the PCR products (Table 2). The hHL 
cDNA (100 ng), 5 µL of both RB2 and RB3 primers (100 µM), and 25 µL of 2X PCR 
Master Mix (Promega, Madison, WI, USA) were mixed with ddH2O for a total volume of 
50 µL and treated to a series of repeated heat cycles. Cycle 1 consisted of denaturation of 
the DNA template at 95°C for 5 minutes. Cycle 2 continued the denaturation for 45 
seconds, followed by an annealing step at 52°C for 1 minute, and an elongation step at 
72°C for 2 minutes. Cycle 2 was repeated for 30 times. Cycle 3 consisted of a single step 
where the reaction temperature remained at 72°C for 5 minutes to ensure that any 
remaining single stranded DNA was fully extended. Once amplified, the product was 
digested with BamHI and HindIII and ligated into the pET32(+) vector (Novagen, 
Madison, WI, USA) (Figure 6) to create the plasmid to express the hHL442-476 fusion 
protein (phHL442-476-Trx).	   The plasmid was sequenced to verify its accuracy (data not 
shown). The phHL442-476-Trx was transformed into the DH5α strain of Escherichia coli 
(Lucigen, Middleton, WI, USA). In brief, 50 µL of chemically competent DH5α cells in a 
1.5 mL microfuge tube with a transformation efficiency of ≥1 × 1010 colony forming units 
per µg DNA were incubated on ice with 10 ng of phHL442-476-Trx for 30 minutes. The 
mixture was then heat shocked, using a heating block at 42°C for 90 seconds. The DH5α 
cell/plasmid mixture was cooled on ice for 10 minutes and 900 µL of Lysogeny Broth 
(LB) (Sigma, St. Louis, MO, USA) was added to the cells and incubated at 37°C, shaking 
at 175 rpm for 90 minutes. Then, 200 µL of cells was plated onto LB agar (Fisher 
Scientific, Ottawa, ON, Canada) plates containing 100 µg/mL sodium ampicillin (Sigma). 
The plates were incubated at 37°C upside down for 18 hours and subsequently stored at  
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Table 2: PCR primer sequences used to create the hHL442-476 peptide. 
 
Forward: RB2 
                        
                     5’-CAATAGGATCCACATTTTGTTCAGAAAACACAGA-3’ 
 
Template 1451……………………………………………………..………1470 
 
 
Reverse: RB3 
                     
                  5’-CTGTTAAGCTTTCATCTGATCTTTTCGCTTTGATGAG-3’ 
 
Template 1555……..……………………………………………….………..1528 
 
 
Primers were designed for LIPC gene (NM_000236). The restriction enzyme cut sites are 
underlined, RB2: BamHI and RB3: HindIII.  
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Figure 6: Schematic of pET32(+) vector used to construct phHL442-476-Trx 
The sequence encoding amino acids 442-476 of hHL was inserted into the pET32(+) 
vector between the HindIII and BamHI sites to create the phHL442-476 plasmid. The 
vector contains an f1 origin to allow for single stranded replication to occur under 
specific conditions. The antibiotic resistance gene used for screening within this vector 
is ampicillin (Ampr). To control the expression of the hHL442-476-Trx protein, the 
vector contains the lac operator and the lacI gene is responsible for its regulation. 
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Figure 6 
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4°C until needed for the expression of the hHL442-476 peptide. 
 
2.1.2 Expression of hHL442-476 peptide 
 
 To express the hHL442-476-Trx protein in bulk, phHL442-476-Trx was transformed 
into OverExpress™ C43(DE3) cells (Lucigen) using the protocol described in section 
2.1.1 for  E. coli DH5α cells. Colonies (5-10) from the LB plates were grown in a 30 mL 
culture of LB containing 100 µg/mL of ampicillin at 37°C in a shaking incubator at 175 
rpm for 18 hours. The culture was then evenly split (with a ratio of 15 mL of overnight 
culture into 1.5 L of fresh LB) and transferred to two flasks, each with 1.5 L of LB 
containing 100 µg/mL of ampicillin. The cultures were grown at 37°C in a shaking 
incubator at 175 rpm until the culture reached an optical density (OD) of 0.6 at 600 nm. 
Then, isopropyl-β-D-1-thiogalactopyranoside (IPTG) (Gold Biotechnology, St. Louis, 
MO, USA) was added to a final concentration of 0.4 mM to allow the hHL442-476-Trx 
protein to be expressed under control of the lac promoter. To allow for maximal protein 
expression, 3 L of bacterial culture at an OD600 nm of 0.6 was further incubated for 18 
hours at 30°C in a shaking incubator at 175 rpm. Following the incubation, the culture 
was divided among four 1 L Nalgene bottles and centrifuged at 5,000 × g for 15 minutes 
to pellet the bacteria. The supernatants were discarded and the pellets were sequentially 
resuspended in 10 mL of 1X Tris-buffered saline (TBS: 6.06 g Tris, 8.76 g NaCl adjusted 
to pH 7.0 and a final volume of 1 L). The bacteria in TBS were lysed using a French press 
at 12,000 psi at 4°C; this step was repeated twice and followed by brief sonication using a 
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probe sonicator (Branson Sonifier 200, Wilmington, NC, USA) with a processor probe at 
setting 7 pulsing the bacteria 3 times for 15 seconds. The lysed bacteria were pelleted at 
5,000 × g for 15 minutes at 4°C to separate the supernatant containing the fusion protein 
from the bacterial cell debris.  
 
2.1.3 Purification of the hHL442-476 peptide 
 
 In order to purify the fusion protein from the other bacterial proteins, the 
supernatant was added to a nickel-sepharose column (capacity of 40 mg/mL) (GE 
Healthcare, Baie d’Urfe, QC, Canada), with a 15 mL column volume (CV); the 
supernatant was incubated for 30 minutes to allow the 6xhis tag to bind to the nickel ions 
on the column. The column flow-through was collected by gravity in 1 mL fractions. 
Non-specific proteins were washed from the column using 3 CV of 40 mM imidazole (in 
1X TBS). The column was further washed with 2 CV of 100 mM imidazole to elute any 
non-specific proteins with a modest affinity to the nickel ions. The hHL442-476-Trx protein 
was eluted from the column using 2 CV of 300 mM imidazole. To determine the purity of 
the hHL442-476-Trx protein, the column fractions were subjected to sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE) (described in section 2.2). Fractions that 
contained the hHL442-476-Trx protein with minimal bacterial protein contaminants were 
pooled and dialyzed using 6,000-8,000 molecular weight cut off (MWCO) tubing (Sigma) 
against 3 L of dialysis buffer (10 mM Tris-HCl, 100 mM NaCl at pH 7.0) at 4°C for 24 
hours to remove the imidazole, exchanging the buffer after 12 hours with a fresh 3 L of 
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dialysis buffer. After dialysis, 30 mL of the fusion protein was incubated with 50 units 
(U) of thrombin (Sigma) at room temperature (RT) for 24 hours on a rocker (VWR, 
Edmonton, AB, Canada) at setting 5. (Five U of thrombin will cleave 1 mg of protein). 
This incubation was done in order to cleave the hHL442-476 sequence from the Trx 
backbone. Specifically, thrombin recognizes the consensus sequence leucine-valine-
proline-arginine-glycine-serine and cleaves between arginine and glycine.86 This results 
in a 7.9 kDa cleaved hHL442-476 peptide linked to both the 6xhis tag and S-tag. To verify 
that the cleavage reaction occurred, SDS-PAGE was performed on uncleaved (15.1 kDa) 
and cleaved (7.9 kDa) reaction samples. Once the correct molecular masses were verified 
from Coomassie Blue stained gels, the cleaved peptide was dialysed using 1,000 MWCO 
tubing (Sigma) against 2 L of 10 mM Na2PO4 at pH 7.0 for 24 hours at 4°C.  
 To separate the cleaved hHL442-476 peptide from the Trx backbone and thrombin in 
the reaction mixture, the mixture was added to a Sephacryl S-100 size exclusion column 
having a column volume of 100 mL equilibrated with 1X phosphate buffered saline (PBS: 
8.7 g NaCl, 2.3 g Na2HPO4, 0.5 g NaH2PO4 adjusted to pH 7.0 and a final volume of 1 L). 
One mL fractions of the column flow-through were collected for up to 100 mL. Fractions 
were assessed by SDS-PAGE using purchased Tris-tricine 16.5% gels (Bio-Rad, 
Mississauga, ON, Canada) to determine the purity of the cleaved hHL442-476 peptide. Size 
exclusion chromatography was first employed to isolate the hHL442-476 peptide; however, 
the method was determined not to be optimal due to the contaminants that co-eluted with 
the hHL442-476 peptide.  
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 To improve the isolation of the cleaved peptide from the Trx protein and 
thrombin, heparin-sepharose (GE Healthcare), was used in all subsequent hHL442-476 
peptide purifications. In brief, the thrombin reaction mixture was dialyzed against 2 L of 
10 mM Na2PO4 at pH 7.0 at 4°C, using 1,000 MWCO dialysis tubing for 24 hours, with a 
change of fresh 2 L of buffer following 12 hours. The thrombin reaction mixture was then 
added to a 15 mL centrifuge tube containing 10 mL of heparin-sepharose (approximately 
40 mg of heparin) in 10 mM Na2PO4 at pH 7.0. The mixture in heparin-sepharose was 
incubated at 4°C for 18 hours on a spinning wheel. Following the incubation, the slurry of 
resin was added to an empty 25 mL column and washed with 4 CV of 10 mM Na2PO4 at 
pH 7.0 to wash proteins not bound to the column; 1 mL fractions were collected by 
gravity. The cleaved hHL442-476 peptide was eluted from the heparin-sepharose column 
with 2 CV of 1.0 M NaCl, (which disrupts the electrostatic interactions between the 
positively charged HBD of the hHL442-476 peptide and the negatively charged heparin-
sepharose). The fractions from the column were assessed using SDS-PAGE. Fractions 
containing the eluted hHL442-476 peptide were pooled and dialyzed against 2 L of 1X PBS 
with 1,000 MWCO tubing at 4°C for 24 hours, with a change of the buffer after 12 hours. 
The concentration was determined using a NanoDrop 2000 spectrophotometer at the 
wavelength at 280 nm (extinction coefficient 125 M-1cm-1). The purified protein was 
divided into 1 mL aliquots and stored at 4°C until needed.  
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2.1.4 Generation of 15N labeled hHL442-476 peptide  
 
  For 15N labeled peptide generation, M9 medium was prepared to culture bacteria 
transformed with the phHL442-476-Trx. The medium contains minimal nutrients with a 15N 
nitrogen source for the bacteria. The recipe for M9 medium is given nutrients per L as 
follows: 6 g Na2PO4 (Sigma), 3 g KH2PO4  (Sigma), 0.5 g NaCl (Fisher Scientific), and 1 
g 15NH4Cl (Cambridge Isotopes, Tewksbury, MA, USA). The pH of the medium was 
adjusted to 7.4 and then autoclaved. Once autoclaved, the following minimal nutrients 
were filter sterilized using 0.22 µm filters (Fisher Scientific) and added to the autoclaved 
medium: 2 mM MgSO4, 0.1 mM CaCl2, 5 mL of 40% w/v glucose, 10 µM FeSO4, 5 mg 
thiamine, and 100 mg ampicillin. Next, 2.5 mL of a stock solution of trace elements was 
added; the stock consisted of 2.7 g FeCl3, 0.2 g ZnCl2, 0.2 g CoCl2, 0.2 g Na2MoO4, 0.1 g 
CaCl2, 0.13 g CuCl2, 0.05 g H3BO3, 10 mL of 10 N HCl, and 90 mL deionized H2O 
(dH2O). After the addition of the trace elements, 1 mL of a stock vitamin mixture was 
added to the medium; the stock consisted of 100 mg biotin, 50 mg choline, 50 mg folic 
acid, 100 mg myo-inositol, 50 mg nicotinamide, 50 mg pyridoxal, 5 mg riboflavin, 50 mg 
thiamine and 100 mL dH2O. 
 An overnight culture of OverExpress™ C43(DE3) cells transformed with 
phHL442-476-Trx was grown as described in section 2.1.2. Following the incubation, the 30 
mL culture was centrifuged at 5,000 rpm for 15 minutes, the supernatant was discarded, 
and the bacterial pellet was used to inoculate 3 L of M9 medium. The inoculated medium 
was incubated at 37°C in a shaking incubator at 175 rpm until the OD600 of the culture 
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reached 0.6. Once the OD was reached, IPTG was added to the culture to a final 
concentration of 0.4 mM; the culture was then incubated at 30°C in the shaker for 18 
hours. Following the incubation, the hHL442-476-Trx was purified and isolated as described 
in section 2.1.3 to obtain the 15N-labeled hHL442-476 peptide. The peptide was 
subsequently analyzed via nuclear magnetic resonance (NMR). 
 
2.2 Sodium Dodecyl Sulfate-Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
 
 For SDS-PAGE preparation, samples were mixed with 4X lysis buffer (5.1 mL 
H2O, 0.08% w/v SDS, 0.4% v/v glycerol, 5 µM bromophenol blue, 0.05% β-
mercaptoethanol) (1:4 dilution for buffer to sample) and boiled for 2 minutes. Samples 
were separated using SDS-PAGE with 4% acrylamide (19:1 ratio) stacking (2 cm) and 
12% acrylamide (19:1 ratio) separating (6 cm) gels for approximately 60 minutes at 200 
V. The running buffer used was Tris/Glycine/SDS (TGS) (25 mM Tris, 192 mM glycine 
and 0.1% w/v SDS, pH 8.3) (Bio-Rad). After separation, the gels were either transferred 
to nitrocellulose membranes for immunoblot analysis or stained with 0.1% w/v 
Coomassie Blue (in 50% v/v methanol 40% v/v H2O, 10% v/v glacial acetic acid) for 
approximately 2 hours on a rocking platform. After staining, the gel was destained using 
the staining solution without Coomassie Blue. However, if protein bands did not appear, 
the gel was subjected to silver stain (Bio-Rad). In brief, the gel was fixed in 15 mL of 
10% ethanol/5% glacial acetic acid (v/v) for 30 minutes, and then washed 4 times (5 
minutes per wash) with 15 mL of dH2O. Once the washes were completed, the gel was 
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incubated with 15 mL silver stain reagent for 15 minutes. The staining reaction was 
stopped with 10% v/v glacial acetic acid.  
 
2.2.1 Immunoblot analysis  
 
 For immunoblot analysis, samples were separated via SDS-PAGE and the gels 
were transferred to nitrocellulose membrane (Bio-Rad) for 2 hours at 350 mA at 4°C with 
a transfer buffer consisting of TGS with 20% v/v methanol (Fisher Scientific). The 
membranes were blocked with filtered blocking solution (5% bovine serum albumin 
(BSA) (Sigma), 0.05% v/v Tween-20 (Sigma), and 0.05% sodium azide (Fisher 
Scientific) in 1X PBS) for 2 hours at RT on a platform rocker. After blocking, membranes 
were incubated with the primary antibody for 3 hours at RT with a dilution of 1:1,000 in 
the 5% blocking solution. Primary antibodies used were: anti-hHL (xHL3-6) (Catalogue 
#sc21740, Santa Cruz Biotechnologies, Santa Cruz, CA, USA), anti-6xhis (H15) 
(Catalogue #sc-803, Santa Cruz Biotechnologies), anti-hLPL (H-53) (Catalogue #sc-
32885, Santa Cruz Biotechnologies), anti-hLPL (F-1) (Catalogue #sc-373759, Santa Cruz 
Biotechnologies), anti-S-tag (Catalogue #8476s, Cell Signaling Technology, Danvers, 
MA, USA), anti-myc-tag (Catalogue #2272, Cell Signaling Technology). After the 
primary antibody incubation, membranes were washed 4 times for 5 minutes per wash 
with 1X PBS-T (1X PBS with 0.05% v/v Tween-20). The membranes were incubated for 
2 hours at RT on a rocking platform with the secondary antibody (1:1,500) diluted in 
blocking solution not containing sodium azide. A donkey anti-rabbit secondary antibody 
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(Catalogue #SA1-100, Fisher Scientific) was used against the primary antibodies, anti-
hLPL (H-53), anti-S-tag, anti-myc-tag and anti-6xhis. A donkey anti-mouse secondary 
antibody (Catalogue #SA1-200, Fisher Scientific) was used against the primary 
antibodies, anti-hHL and anti-LPL (F-1). The membranes were subsequently washed 4 
times for 10 minutes each with 1X PBS. Membranes were subsequently developed with 
ECL Prime Western Blotting Detection Reagent Kit (GE Healthcare), according to the 
manufacturer’s instructions. The membranes were imaged using the chemiluminescence 
setting on an ImageQuant 4000 gel imager (GE Healthcare). 
 
2.3 Mammalian Cell Culture 
 
 2.3.1 HEK-293T cell culture and transfection 
 
 The HEK-293T human embryonic kidney cell line was donated by Dr. Sherri 
Christian (Department of Biochemistry, Memorial University of Newfoundland). The 
cells were maintained at 37°C in an atmosphere of 95% air and 5% CO2 and cultured in 
T75 flasks (BD Biosciences, Mississauga, ON, Canada) at 80% confluency in Dulbecco’s 
Modified Eagle Medium (DMEM) (Catalogue #SH30243.01, HyClone, South Logan, 
UT, USA), 10% v/v fetal bovine serum (FBS) (Catalogue #SH30088.03, HyClone), and 
1% v/v antibiotic/antimycotic (A/A) (Catalogue #SV30079.01, HyClone). Cells were sub-
cultured every 3-4 days. In brief, cells were washed with DMEM (without FBS and A/A) 
and detached from the flask surface using 2.5 mL of 0.25% w/v trypsin (Catalogue 
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#SV3003.01, HyClone). The adhered cells were rinsed with trypsin, then the trypsin was 
discarded; the cells were next incubated for approximately 2 minutes at 37°C in 5% v/v 
CO2. The cells were then detached from the flask by re-suspending them using 10 mL of 
DMEM with 10% FBS and 1% A/A. Cells were divided into a new T75 flask using a 1:10 
ratio of detached cells to DMEM (with 10% FBS and 1% A/A) and incubated at 37°C in 
5% CO2. 
 For the transfection of HEK-293T cells to express lipases, the cells were displaced 
from T75 flasks with trypsin and resuspended in 10 mL of DMEM (10% FBS, 1% A/A) 
but seeded in 100 mm plates (BD Biosciences) to 90% confluency. The cells were 
transfected with 5.85 µg of a pcDNA3 mammalian expression plasmid containing the 
hHL,87 hLPL,87 or myc-tagged hLPL88 cDNA using Optimal Minimal Essential Medium 
(OPTI-MEM) culture media (Invitrogen, Burlington, ON, Canada) and LipofectamineTM 
(Invitrogen) according to the manufacturer’s instructions. Of note, the myc-tag did not 
affect the hydrolytic activity of hLPL (Figure S2). After 5 hours, 5.8 mL of DMEM 
containing 20% FBS and 2% A/A was added to the plates without the removal of the 
plasmid-Lipofectamine™ mixture and incubated for an additional 19 hours. Following 
the 24 hour incubation, spent media was replaced with 5 mL of serum free DMEM 
containing 1% A/A and 10 U/mL heparin (Catalogue #C50430, Fresenius Kabi, 
Richmond Hill, ON, Canada). The plates were further incubated for 23.5 hours in 5% 
CO2 at 37°C. To displace the lipase within the media, the heparin concentration was 
increased to 25 U/mL at 47.5 hours post-transfection. The media was collected in 15 mL 
centrifuge tubes and centrifuged at 750 rpm for 5 minutes to remove any cell debris. The 
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supernatant was divided into 500 µL aliquots and stored at -80°C until needed. The cells 
were washed with 5 mL of 1X PBS to remove any media still on the plates and then 
stored at -80°C. 
 For transfection in 6-well plates, each well received 2.5 µg of lipase plasmid and 
was incubated at 37°C at 5% CO2 for 5 hours. Then, 1.5 mL of DMEM containing 20% 
v/v FBS and 2% v/v A/A was added to each well and plates were incubated for 24 hours 
at 37°C in 5% CO2. The spent media was discarded and the cells were washed once with 
1 mL of DMEM. Then, 1.5 mL of fresh DMEM was added to the cells and incubated for 
additional 24 hours at 37°C in 5% CO2. Transfected cells were subsequently used for 
lipase displacement assays (see section 2.4.2). 
 
2.4 Functional Analysis of the hHL442-476 Peptide  
 
2.4.1 Heparin-sepharose assay with NaCl step-wise gradient 
 
 The hHL442-476 peptide was expressed and purified as described in section 2.1.3. 
Twenty µg of the hHL442-476 peptide was added to 500 µL of heparin-sepharose in a 1.5 
µL microfuge tube and mixed for 18 hours at 4°C on a spinning wheel. The tube was 
subsequently centrifuged at 2,000 rpm for 3 minutes to isolate the supernatant. The resin 
was then washed 6 times with 200 µL of 10 mM Na2PO4, pH 7.0 for 2 minutes per wash 
on the spinning wheel at 4°C. After each wash, the sample was centrifuged at 2,000 rpm 
for 3 minutes and the supernatant from all washes was collected. Following the washes, 
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the heparin-sepharose was incubated with 200 µL of a NaCl solution in a step-wise NaCl 
gradient, starting at 0.1 M NaCl and ending at 1.0 M NaCl, in increments of 0.1 M. Each 
incubation was for 15 minutes at 4°C on the spinning wheel. After each of the NaCl 
incubations, the slurry was centrifuged for 3 minutes at 2,000 rpm, and the supernatant 
was collected. All samples were subjected to SDS-PAGE analysis, as described in section 
2.2. 
 
2.4.2 Lipase displacement assay 
 
 HEK-293T cells were grown to 80% confluency and detached with trypsin (as 
described in section 2.3.1). Cells were resuspended in 20 mL of DMEM (with 10% FBS 
and 1% A/A). The cells were seeded into 6-well plates (Fisher Scientific) in a volume of 
2.5 mL. Plates were incubated for 18 hours at 37°C in 5% CO2. After 18 hours, the cells 
were transfected to express hHL, or hLPL, as described in section 2.3.1. On the 4th day 
post-transfection, HEK-293T cells were transferred to a 4°C cold room and washed 3 
times with 1 mL of ice cold DMEM (without FBS and A/A). Following the washes, each 
plate of the cells was incubated for 1 hour at 4°C with 1 mL DMEM (without FBS and 
A/A) ± 200 µg/mL of the hHL442-476 peptide. Prior to the addition of the hHL442-476 
peptide to the cells, the hHL442-476 peptide was desalted and collected in plain DMEM 
using a PD-10 desalting column as per the manufacturer’s instructions (GE Healthcare). 
After the 1 hour incubation without or with peptide, the treatment media was collected. 
The cells were washed with 3 times ice cold DMEM (without FBS and A/A). Next, three 
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wells were incubated with 1 mL of DMEM (without FBS and A/A), the remaining three 
wells received 1 mL of DMEM (without FBS and A/A) containing 100 U of heparin and 
incubated for 1 hour at 4°C. The media were collected and stored in microfuge tubes at  
-80°C until needed. The cells were washed once with 1X PBS then the cells were stored 
at -80°C. All of the samples (media and cells) were analyzed by immunoblot analysis, as 
previously described in section 2.2.1. To lyse the cells, 1 mL of 4X lysis buffer was added 
to each well and the cells were scraped using cell scrapers (Fisher Scientific). A 1:4 
dilution with more 4X lysis buffer was done to analyze the cells via immunoblot. The cell 
lysates were stored at -80°C until required again. 
 
2.5 Lipase Activity 
 
2.5.1 Resorufin ester assay 
 
 To evaluate the activity of the lipases from the media of transfected cells (as 
described in section 2.3.1), an assay measuring the hydrolysis of a resorufin ester was 
performed.89 First, a stock solution for the substrate 1,2-O-dilauryl-rac-glycero-3-glutaric 
acid-resorufin ester (Sigma) was prepared by dissolving 2 mg of the resorufin ester in 1 
mL of dioxane (Sigma); the stock solution of substrate was stored at 4°C until needed. 
For the assay, the stock solution was diluted to 0.3 mg/mL in the reaction buffer (20 mM 
Tris, 1 mM EDTA, pH 8.0); 20 µL of the diluted substrate was used per reaction. To 
assess lipase activity, 75 µL of the heparinized media from HEK-293T cells expressing 
	   	   	  47	  
lipases was pipetted into the well of a 96-well microtitre plate (Fisher Scientific), 
followed by the addition of 105 µL of the reaction buffer and 20 µL of the diluted 
resorufin ester. The absorbance at 572 nm was read every 3 minutes for a 1 hour period at 
25°C using a microtiter plate reader. A standard curve for determining resorufin 
concentration was created, using 0, 1, 2, 3, 4, 6, 10, 15, 20, 30, and 40 µM resorufin 
(Sigma), dissolved in the reaction buffer to a final volume of 200 µL. 
 
2.6 Structural Analysis of Mimetic Peptide 
 
2.6.1 Secondary structure: circular dichroism  
 
 Samples of the cleaved peptide for circular dichroism (CD) were prepared, as 
described above in section 2.1.3. The sample was lyophilized and 0.1 mg was dissolved in 
1 mL of dH2O and 160 µL was pipetted into a 0.5 mm CD cuvette for analysis in a Jasco 
J-810 CD spectrophotometer. The sample was initially subjected to 10 scans, while 
ensuring that the high tension (HT) voltage did not exceed 700 volts, which would 
indicate too much scatter from the sample and not enough light passing through the 
sample. If the HT voltage exceeds 700 volts, the spectrum obtained becomes noisy and 
unreliable. Once the scans were complete, either heparin or trifluoroethanol (TFE) was 
titrated into the sample within the cuvette. In the case of heparin, 100 U was titrated in 
and analyzed over 10 scans, followed by increasing the heparin concentration to 250 U 
for re-analysis over 10 scans. For the TFE titrations, 5, 10, 20, 30, and 40% v/v of TFE 
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was titrated into the sample and 10 scans were performed after each amount of TFE was 
added. Once the scans were finished, the raw data were plotted in Microsoft Excel (Mac 
2010) to produce the CD spectra. 
   
2.6.2 1H-NMR sample preparation 
 
  The cleaved peptide was expressed and purified as described in section 2.1.3. 
Following the heparin-sepharose purification, the peptide was dialyzed with 1,000 
MWCO dialysis tubing against 2 L of low sodium phosphate buffer (1 L: 2.9 g NaCl, 2.3 
g Na2HPO4, 0.5 g NaH2PO4, pH 7.0) for 24 hours at 4°C, with buffer exchange after 12 
hours. Following dialysis, the protein solution was lyophilized. Specifically, the dialyzed 
sample was put in a beaker and placed in liquid nitrogen to freeze the sample to avoid any 
bumping out and loss of the sample once the vacuum of the freeze dryer was applied. The 
sample was applied to the freeze dryer and left for 48 hours. After the sample was 
lyophilized, the mass of the powder was determined and the powder was stored in a 
sealed vial at 4°C until needed. For 1H-NMR, 1.5 mg of the lyophilized sample was 
dissolved in 1 mL of dH2O. The pH was determined for each sample prior to analysis 
using pH indicator strips (Sigma). This was done to rule out any structural anomalies 
observed due to the pH of the sample. The total volume for the NMR sample was 600 µL, 
and it contained 90% H2O, 10% v/v deuterium oxide (D2O) (Sigma) and 0.4 mM 4,4-
dimethyl-4-silapentane-1-sulfonic acid (DSS) (Cambridge Isotopes Laboratories, Inc., 
Tewsbury, MA, USA). The sample was pipetted into an NMR tube (New Era Enterprises, 
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Inc., Vineland, NJ, USA) and placed in the NMR machine, Bruker AVANCE II 600 
(Bruker, Billerica, MA, USA) with a 600 MHz probe. 1H-NMR of the samples was 
carried out either at 4°C or 25°C, in the absence or presence of either heparin or 
deuterated TFE (Cambridge Isotopes Laboratories, Inc.). Table 3 lists the experiments 
that were conducted in order. Experiment 1: 1 dimensional (1D) 1H spectrum with water 
suppression was conducted to achieve a spectrum without the large signal that water 
produces. Experiment 3: 2 dimensional (2D) nuclear Overhauser effect spectroscopy 
(NOESY) with peptide was conducted to determine through-space interactions. 
Experiment 7: total correlation spectroscopy (TOCSY) was conducted to indicate 
through-bond correlations. After the initial set of NMR experiments was performed with 
the hHL442-476 peptide, select NMR experiments were performed with heparin added to 
the samples. Specifically, 100 U of heparin was titrated into the sample and the 
experiments were conducted (experiment 4), then the heparin concentration was increased 
to 250 U and experiments 5-7 were carried out. Then, a new sample was prepared for 
experiments 8-16 and varying percentages of TFE (5, 10, 20, and 30% v/v) were titrated 
in and experiments were run after each percentage of TFE was added. The same sample 
used in experiments 5-7 was used for experiment 17. For experiments 19 and 20, a 15N 
labeled hHL442-476 peptide was generated as described in section 2.1.4. Once experiments 
were finished, the spectra were analyzed using iNMR software. 
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Table 3: List of NMR experiments conducted with the hHL442-476 peptide  
 
NMR Experiment Parameters Filename 
1. 1D-1H water suppression with peptide 25°C, recycle delay 2s, scans 224, 
receiver gain 1150 
A2 
peptide/2 
2. 1D-1H water suppression with peptide 5°C A2 
peptide/3 
3. 2D-1H NOESY with peptide 25°C, 112 scans, number of 
points 1024 by 386 
A2 
peptide/4 
4. 1D-1H water suppression with peptide and 100 U 
heparin 
25°C A2 
peptide/5 
5. 1D-1H water suppression with peptide and 250 U 
heparin 
25°C A2 
peptide/6 
6. 2D -1H NOESY with peptide and 250 U heparin 25°C, 122 scans, number of 
points 1024 by 400 
A2 
peptide/7 
7. 2D-1H TOCSY with peptide and 250 U heparin 25°C, 136 scans, number of 
points 1024 by 5  
mixing time 60 µs 
A2 
peptide/8 
8. 1D-1H water suppression 5% TFE and peptide 25°C A2 
peptide/10 
9. 1D-1H water suppression 5% TFE and peptide 5°C A2 
peptide/11 
10. 1D-1H water suppression 10% TFE and peptide 5°C A2 
peptide/12 
11. 1D-1H water suppression 10% TFE and peptide 25°C A2 
peptide/13 
13. 2D-1H NOESY 10% TFE and peptide 25°C, 112 scans, number of 
points 1024 by 364 
mixing time 300 µs 
A2 
peptide/14 
14. 1D-1H water suppression 20% TFE and peptide 25°C A2 
peptide/15 
15. 1D-1H water suppression 20% TFE and peptide 5°C A2 
peptide/16 
16. 1D-1H water suppression 30% TFE and peptide 5°C A2 
peptide/17 
1H- 15N-NMR Experiments   
19. 1H-15N HSQC (heteronuclear single quantum 
coherence) with peptide 
5°C, scans 409, number of points 
1024 by 109, receiver gain 1030, 
relaxation delay 1s 
A2 conc. 
Aug 4 / 3 
20. 1H-15N HSQC with peptide and 250 U heparin 5°C scans 409, number of points 
1024 by 109, receiver gain 1030, 
relaxation delay 1s 
A2 
conc.+250 
U Heparin 
Aug 4 / 3 
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2.7 Statistical Analysis  
 
  The p-values presented in figures were determined using a one-way ANOVA 
with a Tukey’s test for multiple comparisons, calculated using Excel; a p-value of less 
than 0.05 was taken to be significant. The error bars were generated by using the standard 
deviation of the mean. 
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Chapter 3: Results 
 
 
3.1 Expression and Isolation of the hHL442-476 Peptide 
  
 The phHL442-476-Trx plasmid was transformed into the OverExpress™ C43(DE3) 
strain of E. coli and the expression of hHL442-476-Trx protein was achieved at 30°C in the 
presence of 0.4 mM IPTG (Figure 7A). Figure 7A also shows that the hHL442-476-Trx 
oligopeptide was not expressed in the absence of IPTG. To isolate the hHL442-476-Trx 
protein from the supernatant of pelleted OverExpress™ C43(DE3) cell lysates, the 
supernatant was subjected to nickel-sepharose chromatography. The elution of the 
hHL442-476-Trx protein was achieved with 300 mM imidazole (Figure 7B). Following 
isolation by nickel-sepharose chromatography, the hHL442-476-Trx protein was incubated 
with thrombin to cleave the hHL442-476 sequence from Trx, yielding the hHL442-476 peptide 
with a theoretical molecular mass of 7.9 kDa (Figure 7C). However, the hHL442-476 
peptide has an experimental molecular weight of approximately 12 k. The discrepancy 
between the two values is a consequence of the hHL442-476 peptide having numerous 
positively charged amino acids (lysines and arginines) that allows it to migrate slower in 
SDS-PAGE due to a reduction in the charge-to-mass ratio.90 The 12 k band was 
confirmed to be the hHL442-476 peptide by immunoblot analysis using the S-tag antibody 
(data not shown). Also observed in Figure 7C is thrombin at approximately 29 kDa. This 
is representative of the B chain of thrombin (31 kDa); the A chain (6 kDa) is joined by a 
disulfide bridge and under reducing conditions is not observed. The Trx protein (15.1 
kDa) is not observed. These results show that the hHL442-476-Trx protein can be expressed  
	   53	  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7: Expression and isolation of hHL442-476 peptide from E. coli C43(DE3)  
A) OverExpress™ C43(DE3) cells were transformed with the phHL442-476-Trx plasmid. 
Cells were inoculated in 15 mL of LB broth and grown to mid-log phase at 37°C, 
followed by an incubation for 18 hours at 30°C with (+) or without (-) 0.4 mM ITPG. 
The presence of the hHL442-476-Trx protein is observed as a distinct band at 25 kDa on a 
Coomassie Blue stained 12% acrylamide gel (indicated with “*”). B) hHL442-476-Trx 
protein was isolated using nickel-sepharose chromatography. The supernatant (S) was 
applied to the column and the flow-through (FT) was passed through by gravity. The 
column was then washed 3X with 1X TBS (pH 7.0) containing 40 mM imidazole (W1-
3). The column was washed twice with 1X TBS (pH 7.0) containing 100 mM imidazole 
(W4-5). Finally, the 23 kDa hHL442-476-Trx protein was eluted from the nickel-sepharose 
column with 1X TBS (pH 7.0) containing 300 mM imidazole. The proteins from the 
nickel-sepharose column were separated by SDS-PAGE with 12% acrylamide and 
stained with Coomassie Blue. C) The nickel-sepharose eluent containing the hHL442-476-
Trx protein was pooled (30 mL) and incubated with 50 U of thrombin for 18 hours at 
room temperature on a shaker. Following the incubation, samples were analyzed by SDS-
PAGE with 12% acrylamide and stained with Coomassie Blue. FP = fusion hHL442-476-
Trx protein, CP= cleaved hHL442-476 peptide 
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Figure 7 
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Figure 7 (cont.) 
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and that the hHL442-476 peptide can be subsequently cleaved from the hHL442-476-Trx 
protein.  
 To isolate the hHL442-476 peptide from the 15.1 kDa Trx protein and the 37 kDa 
thrombin enzyme, a Sephacryl S-100 size-exclusion column was used. Figure 8 indicates 
that the fractionation of the hHL442-476 peptide did not successfully purify the hHL442-476 
peptide from Trx and thrombin. There are also other bacterial protein contaminants with 
higher molecular masses that are present in fractions 40 and 45. Since the size-exclusion 
chromatography was unsuccessful in the isolation of the hHL442-476 peptide, heparin-
sepharose chromatography was then tried. Heparin-sepharose is a resin that mimics 
HSPGs that are present at the cell surface; proteins with affinity to heparin-sepharose are 
released by buffers with a high ionic strength. Figure 9 shows the elution of the hHL442-476 
peptide with 1.0 M NaCl, as seen by a single band. These results demonstrate that the 
hHL442-476 peptide can be successfully cleaved from Trx and subsequently purified by 
heparin-sepharose chromatography. 
 
3.2 Optimal Heparin-Sepharose Association of the hHL442-476 Peptide 
  
 Having shown that the hHL442-476 peptide can be eluted from heparin-sepharose 
with a high 1.0 M NaCl concentration, a step-wise NaCl gradient was used to determine 
the optimal amount of NaCl required to dissociate the hHL442-476 peptide from heparin-
sepharose. As shown in Figure 10A, the hHL442-476 peptide elutes from heparin-sepharose 
once the NaCl gradient begins (starting at 0.1 M), with the peak of elution at 0.3 M NaCl  
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Figure 8: Isolation of hHL442-476 peptide from thioredoxin protein by size-
exclusion chromatography 
Approximately 30 mL of pooled fractions from the nickel-sepharose column 
containing the hHL442-476 peptide, Trx protein and thrombin were lyophilized, 
resuspended in 2 mL of 1X PBS (pH 7.0), and loaded onto a size exclusion Sephacryl 
S-100 column that was pre-equilibrated with 1X PBS (pH 7.0). One mL fractions were 
collected from the column and the presence of the hHL442-476 peptide was analyzed by 
SDS-PAGE with 0.05% β-mercaptoethanol using a Tris-tricine gradient gel (4-16%) 
stained with Coomassie Blue. The hHL442-476 peptide was observed in fractions (F) 40-
55, denoted by “*”. 
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Figure 8 
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Figure 9: Isolation of hHL442-476 peptide from thioredoxin protein by heparin-
sepharose chromatography  
The cleavage reaction containing the hHL442-476 peptide, Trx and thrombin was 
dialyzed against 10 mM sodium phosphate (pH 7.0) then incubated with heparin-
sepharose resin, as described in section 2.1.3. Following incubation, the resin was 
packed into a PD-10 column and the flow-through (FT) was collected by gravity. The 
column was washed with 4 CV (10 mL) of 10 mM sodium phosphate (pH 7.0) (W1-4). 
Following the washes, the hHL442-476 peptide was eluted with 1.0 M NaCl. The 1 ml 
fractions were collected from the column and 20 µL were analyzed for the presence of 
the hHL442-476 peptide by 12% SDS-PAGE and stained with Coomassie Blue. The 
elution of the hHL442-476 peptide is denoted by “*”.  
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Figure 9 
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Figure 10: Optimal elution of the hHL442-476 peptide from heparin-sepharose 
under reducing and non-reducing conditions 
The hHL442-476 peptide (20 µg) was incubated with 200 µL of heparin-sepharose at 4°C 
for 18 hours either in the absence (panels A and B) or presence (panels C and D) of 
0.5% v/v β-mercaptoethanol. Following the 18 hour incubation, the heparin-sepharose 
beads were pelleted and the supernatant was collected, then the heparin-sepharose was 
treated with a step-wise NaCl gradient as described in section 2.4.1. Fractions were 
analyzed by 12% SDS-PAGE and stained with Coomassie Blue. A) Elution of hHL442-
476 peptide from heparin-sepharose under non-reducing conditions. B) Band intensities 
were quantified from A using ImageJ software. Individual band intensities are 
represented as a percentage of the total individual band intensities. C) Elution of 
hHL442-476 peptide from heparin-sepharose under reducing conditions. D) Band 
intensities were quantified using ImageJ software. Individual band intensities are 
represented as a percentage of the total individual band intensities. 
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Figure 10 
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(Figure 10A & B). To investigate whether the two cysteine residues within the hHL442-476 
peptide form a disulfide bridge that influences the heparin-sepharose association, the 
assay was also conducted under reducing conditions. The data from Figure 10C & D 
strongly suggest that the putative disulfide bridge is not required for the optimal 
association of the hHL442-476 peptide to heparin-sepharose, as indicated by the very similar 
elution profiles of the hHL442-476 peptide under both reducing and non-reducing 
conditions.  
 
3.3 Displacement of Cell Surface Associated Lipases by the hHL442-476 Peptide 
  
 To investigate if the hHL442-476 peptide has the ability to displace cell surface 
associated hHL, 200 µg/mL of hHL442-476 peptide was incubated with HEK-293T cells 
overexpressing hHL at 4°C. The media were analyzed for displaced hHL lipase activity 
using a resorufin ester hydrolysis assay and qualitatively by immunoblot analysis. The 
lipase activity data for hHL in Figure 11A indicates that the hHL442-476 peptide does 
displace active hHL from cell surfaces compared to the DMEM control. However, the 
hHL442-476 peptide displaces less hHL from cell surfaces compared to the 100 U/ml 
heparin control. An immunoblot confirms the activity data, the hHL442-476 peptide does 
not displace as much hHL from cell surfaces, as the 100 U/ml heparin control (Figure 
11B).  
 In order to assess if the hHL442-476 peptide is specific and only displaces hHL from 
cell surfaces, the hHL442-476 peptide was also tested against another cell surface associated  
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Figure 11: Displacement of hepatic lipase by the hHL442-476 peptide  
Six well plates containing transfected HEK-293T cells expressing hHL were incubated 
for 1 hour at 4°C with plain DMEM (negative control), DMEM containing 200 µg/mL 
hHL442-476 peptide, or DMEM containing 100 U/mL heparin (positive control). 
Following the incubation, the media and cells were collected. A) The media were 
analyzed for lipase activity using a resorufin ester substrate. Data are presented as the 
µM resorufin released per minute. n=3. *, p<0.005 versus DMEM control. B) 
Immunoblot analyses of media, using the primary anti-hHL antibody XHL3-6. 
Proteins from triplicate experiments were separated – one experimental sample per 
lane. 
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lipase. hLPL was chosen as a control for the hHL442-476 peptide due to the pro-atherogenic 
properties hLPL possesses.91-93 Considering the pro-atherogenic properties of 
hLPL,displacing active hLPL from cell surfaces with the hHL442-476 peptide could 
potentially increase the risk of atherosclerosis. This is why testing the ability of the 
hHL442-476 peptide to displace cell surface associated hLPL in vitro is necessary. When 
200 µg/mL of the hHL442-476 peptide was incubated with  HEK-293T cells overexpressing 
myc-tagged hLPL, the activity data from the cells indicates that the hHL442-476 peptide 
does displace hLPL (Figure 12). However, the hLPL activity detected by the cells treated 
with the hHL442-476 does have less detectable activity when compared to the 100 U/mL 
heparin control. 
 An immunoblot of the hLPL displaced by the hHL442-476 peptide was not obtained. 
The polyclonal hLPL antibody (H-53) produced immunoblots with a lot of non-specific 
binding to the membrane, creating unreliable immunoblots (Figure S3). A monoclonal 
hLPL antibody (F-1) was then tried to detect the presence of the hLPL in the media and 
the cells of transfected cells compared to the mock control (Figure S4). The immunoblot 
shown in Figure S4 indicates that the monoclonal hLPL antibody was also non-specific. 
Considering the difficulty encountered with obtaining an immunoblot for both the hLPL 
and hLPL-myc displacements, it is speculated that the amount of hLPL displaced into the 
media at 4°C is not enough to detect by immunoblot.  
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Figure 12: Displacement of lipoprotein lipase by the hHL442-476 peptide  
Six well plates containing transfected HEK-293T cells expressing myc tagged human 
LPL were incubated for 1 hour at 4°C with plain DMEM (negative control), DMEM 
containing 200 µg/mL hHL442-476 peptide, or DMEM containing 100 U/mL heparin 
(positive control). Following the incubation, the media were analyzed for lipase 
activity using a resorufin ester substrate. Data are presented as the µM resorufin 
released per minute. n=3. *, p<0.005 versus DMEM control. 
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3.4 Structural Analysis of the hHL442-476 Peptide 
 
In an attempt to identify the structural elements of the C-terminal amino acids of 
hHL that account for the cell surface binding, the hHL442-476 peptide was subjected to CD 
and NMR analyses. CD spectra for the hHL442-476 peptide indicate that the peptide does 
not have the characteristic secondary structure of an α-helix or a β-sheet, but rather that it 
is relatively unstructured. As shown in Figure 13, the hHL442-476 peptide has a single 
minimum at 200 nm, which is consistent with the spectrum of a peptide with a random 
coil secondary structure.94 The observed lack of secondary structure in the hHL442-476 
peptide was also apparent in the presence of 250 U of heparin (Figure 13). The secondary 
structure of the hHL442-476 peptide was further assessed in the presence of the structure 
inducing agent TFE (Figure 14). The CD spectra of the hHL442-476 peptide in increasing 
concentrations of TFE show that the peptide adopts a more α-helical structure, as 
indicated by the minimum at 200 nm shifting towards 210 nm and resembling a double 
minima that are characteristic of an α−helical secondary structure.94 Overall, the CD 
experiments indicate that the hHL442-476 peptide is mostly unstructured but it does have the 
ability to adopt a more α-helical ordered structure.  
 In order to gain information about the tertiary structure of the hHL442-476 peptide, 
1H-NMR was used. At 25°C, almost no peaks could be observed for the hHL442-476 
peptide within the H-N region (approximately 6.0 ppm to 10.0 ppm) (Figure 15). In an 
attempt to observe more peaks, the temperature was lowered to 5°C. The 1H-NMR 
spectrum obtained resembles the spectrum for the hHL442-476 peptide at 25°C, thus  
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Figure 13: Determining secondary structure of the hHL442-476 peptide using 
circular dichroism in the presence and absence of heparin 
The hHL442-476 peptide (0.1 mg/mL, pH 6.5) was added to a 0.5 mm CD cuvette and 
analyzed with 10 scans by the CD spectrophotometer. Following the 10 scans, 250 U 
heparin was titrated into the hHL442-476 peptide sample and subjected to additional 10 
scans. 
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Figure 14: Analyzing the secondary structure of hHL442-476 peptide using circular 
dichroism by titrating in trifluoroethanol (TFE) 
The hHL442-476 peptide (0.1 mg/mL, pH 6.5) in 5% v/v TFE was added to a 0.5 mm CD 
cuvette. The sample was analyzed with 10 scans of the CD spectrometer. Following 
the 10 scans, the TFE percentage was increased to 10% v/v and another 10 scans were 
recorded. This procedure was repeated as indicated until the percentage of TFE was 
40% v/v.  
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Figure 14 
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Figure 15: Determining structural components of the hHL442-476 peptide using 1H-
NMR with varying temperatures 
The hHL442-476 peptide (1.5 mg) was reconstituted in 1 mL of 90% dH2O and 10% 
D2O, and analyzed at A) 25°C and B) 5°C, both with 1D water suppression (250 
scans). The spectra were Fourier transformed and phase corrected. The box highlights 
the H-N region.  
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Figure 15 (cont) 
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indicating that the peptide does not become more structured when the temperature is 
decreased. To further investigate the structural components of the hHL442-476 peptide, the 
structure inducing effect of TFE was assessed with the next set of 1H-NMR experiments. 
The spectra in Figure 16A and 16B indicate that TFE (5% and 30% v/v) does not have 
any effect on the tertiary structure of the hHL442-476 peptide. Figure 16C also indicates that 
lowering the temperature to 5°C does not have any effect on its tertiary structure. The 
lack of peaks in the H-N region of the spectrum is consistent with a peptide that is neither 
completely structured nor completely unstructured. Instead, the hHL442-476 peptide 
appears to be in an intermediate state where it is interconverting between different 
conformations and exchanging between these different conformations on an intermediate 
timescale. 
 The addition of 250 U of heparin did induce some changes in the structural 
preferences of the hHL442-476 peptide at 25°C (Figure 17). This is indicated by the 
increased intensity of the peaks within the H-N region, specifically at 6.00, 7.25 and 8.40 
ppm (Table 4). Based on their chemical shifts, as well as their line widths, that are greater 
than would be expected from small molecule contaminants, the new peaks are most likely 
from the hHL442-476 peptide. Their appearance indicates that heparin induces a change in 
the structural preferences of the hHL442-476 peptide, thus heparin induces a greater level of 
defined structure in the peptide than is apparent in its absence. The two prominent peaks 
at 7.0 and 8.0 ppm are most likely from the heparin molecule itself.  
 Two-dimensional TOCSY-NMR was next used to gain information about the 
hHL442-476 peptide via bond correlations, Figure 18. The crosspeaks (i.e., the peaks not on  
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Figure 16: Determining structural components of the hHL442-476 peptide using 1H-
NMR with varying concentrations of TFE 
The hHL442-476 peptide (1.5 mg) was reconstituted in 1 mL of 90% dH2O and 10% 
D2O, in the presence of A) 5% v/v TFE at 25°C and B) 30% v/v TFE at 25°C. C) 30% 
v/v TFE at 5°C. 1D water suppressions were run for 250 scans. The resulting spectra 
were Fourier transformed and phase corrected. The box highlights the H-N region. 
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Figure 16 (cont) 
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Figure 16 (cont) 
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Figure 17: Determining structural components of the hHL442-476 peptide using 1H-
NMR with 250 U of heparin 
The hHL442-476 peptide (1.5 mg) was reconstituted in 1 mL of 90% dH2O and 10% 
D2O. 1D water suppression was run for 250 scans at 25°C. Following the 250 scans, 
heparin was added to 250 U/mL and the sample was assessed for 250 scans at 25°C. 
The resulting spectra were Fourier transformed and phase corrected. The box 
highlights the H-N region, and “*” denotes the peaks that have changed upon the 
addition of heparin 
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Table 4: Peaks from the H-N region of the 1H-NMR of the hHL442-476 peptide upon 
addition of 250 U heparin at 25°C 
 
 
 
Molecule 
 
Peaks (ppm) 
 
 
hHL442-476 peptide 
 
6.00 
 
7.25 
 
8.40 
 
 
Heparin 
 
7.00 
 
8.00 
 
Highlighted are the peaks that increased in both intensities and peak with upon the addition of 
250 U of heparin within the H-N region of the spectrum. Also listed are the two prominent 
peaks due to heparin.  
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Figure 18: Determining structural components of the hHL442-476 peptide using 1H-
NMR total correlation spectroscopy with 250 U of heparin  
The hHL442-476 peptide (1.5 mg) was reconstituted in 1 mL of 90% dH2O and 10% 
D2O. 2D TOCSY of the hHL442-476 peptide with 250 U of heparin was run at 25°C. The 
resulting spectra were Fourier transformed and phase corrected. The circle highlights 
the peaks that are induced by heparin.  
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 the diagonal line) in the TOCSY-NMR spectrum of the hHL442-476 peptide indicate pairs 
of hydrogen nuclei within 3 covalent bonds of each other – i.e. within the same amino 
acid. The large line that runs down the left side of the spectrum at about 7 ppm belongs to 
heparin, very similar to what is observed in Figure 17. One plausible explanation for the 
correlation patterns highlighted within the circle is they derive from interactions that are 
not typical of the amino acids found in the peptide’s sequence. However, arginine usually 
has an amide sidechain proton peak that is observed around 7.2 ppm. These highlighted 
peaks observed could be shifted up-field to roughly 8.2 ppm because they are interacting 
with heparin. 
 In addition to the TOSCY-NMR, an additional two-dimensional NMR method 
was used in an attempt to gain further information about the hHL442-476 peptide. NOESY-
NMR, which yields information about protons that are close in space although possibly 
distant in the amino acid sequence was used. Figure 19 shows the spectrum of the hHL442-
476 peptide in the presence of 250 U heparin. Identifying specific peaks from the spectrum 
is difficult due to a significant amount of background signal. However, the identification 
of unique peaks that are observed both in the TOCSY and in the NOESY spectra indicate 
that nuclei are close through bond and in space. This could represent the arginines present 
in the hHL442-476 peptide, which are close through both bond and space that they may be 
associating with the heparin. 
 Lastly, a 15N-labeled version of the hHL442-476 peptide was generated for 
heteronuclear single quantum correlated spectroscopy (HSQC)-NMR (Figure 20), in 
order to obtain further structural data via correlation information between nitrogen and  
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Figure 19: Determining structural components of the hHL442-476 peptide using 1H-
NMR nuclear Overhauser effect spectroscopy with 250 U of heparin 
The hHL442-476 peptide (1.5 mg) was reconstituted in 1 mL of 90% dH2O and 10% 
D2O. 2D NOESY of the hHL442-476 peptide with 250 U of heparin was run at 25°C. The 
resulting spectra were Fourier transformed and phase corrected. The circle highlights 
the peaks that are induced by heparin.  
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Figure 20: Determining structural components of the hHL442-476 peptide using 1H-
15N NMR heteronuclear single quantum correlation spectroscopy with and 
without heparin 
The hHL442-476 peptide (1.5 mg) was reconstituted in 1 mL of 90% dH2O and 10% 
D2O. The HSQC of the hHL442-476 peptide was run at 25°C in the absence (blue) or 
presence (green) of 250 U of heparin. Highlighted is the chemical shift that occurred 
due to the addition of heparin.  
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the amide protons. Figure 20 shows HSQC-NMR spectra for the hHL442-476 peptide in the 
absence of the amide protons. The shows the HSQC-NMR spectra for the hHL442-476 
peptide in the absence of heparin (blue) and in the presence of 250 U heparin (green). In 
the absence of heparin, few peaks are observed and the backbone H-N peaks (everything 
except for the top, right hand side of the spectrum) are not very dispersed, indicative of an 
unstructured peptide. However, upon the addition of heparin, many more protein peaks 
are visible and they are well dispersed, representing a more structured peptide. 
Highlighted at the bottom of Figure 20 is a peak that is found both in the absence and 
presence of heparin and perhaps shifts slightly upon heparin binding. Overall, these NMR 
experiments indicate that in the absence of heparin the hHL442-476 peptide does not assume 
a defined conformation. However, the addition of heparin appears to cause the hHL442-476 
peptide to undergo a conformational change, due to the appearance of unique chemical 
shifts (Table 4). Additionally, at least some of the chemical shift patterns do not 
correspond to what is typically observed and thus may indicate an unusual structure that 
the hHL442-476 peptide uses to bind to heparin.   
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Chapter 4: Discussion 
 
 
4.1 Functional Analysis of the hHL442-476 Peptide 
 
 
4.1.1 Optimal heparin-sepharose association of the hHL442-476 peptide 
 
 
 The association of proteins to heparin-sepharose is used to characterize heparin 
binding proteins. The molarity of NaCl used to elute a protein from heparin-sepharose is 
generally proportional to the protein’s dissociation constant.95 The full-length dimer of 
hHL has been shown to elute from heparin-sepharose at 0.7 M NaCl.73 In contrast, the 
full-length dimer of hLPL has a stronger association that requires 1.1 M NaCl for 
elution.96 The biological significance of the differences in the heparin-sepharose 
association of the lipases remains unclear. The association of the hHL442-476 peptide 
containing the major HBD75 to heparin-sepharose was tested and was observed to be 
disrupted by 0.3 M NaCl, both under reducing and non-reducing conditions (Figure 10). 
This demonstrates that the hHL442-476 peptide has a much lower association to heparin-
sepharose compared to full-length hHL and that the putative disulfide bridge within the 
HL442-476 peptide is not required for its association. Thus, the last 34 amino acids from 
hHL alone are not sufficient to reconstitute the heparin binding properties of full-length 
hHL. Although the hHL442-476 peptide may contain the heparin binding motifs depicted in 
Figure 6B, the full-length hHL protein appears to require multiple HBDs to retain the 
optimal cell surface binding and heparin-sepharose association.  
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The current study is the first study to specifically investigate the last 34 amino 
acids of the C-terminal of hHL, although there have been other studies that have 
investigated the HBDs of hHL.74,75 Brown et al. investigated a truncated hHL mutant, 
hHL471, that was missing the last five amino acid residues of the C-terminal (KRKIR); 
they showed that it exhibited a decreased cell surface association, such that 40% of the 
extracellular hHL471 protein was released in the absence of heparin.75 This suggests that 
the last 5 amino acids within the C-terminal 34 amino acids of hHL are critical for cell 
surface binding. 
 The weaker association of the hHL442-476 peptide to heparin-sepharose could be a 
result of many different factors. Brown et al. observed that when the last 70 C-terminal 
amino acids from hHL were switched with the analogous sequence from mHL, the 
chimeric protein had a 20-fold decrease in cell surface association compared to wild-type 
hHL.75 The 20-fold decrease in cell surface association indicates that the C-terminal of 
hHL contains a major HBD. However, Yu and Hill have also identified a HBD located in 
the N-terminal part of hHL.74 This HBD might also be contributing to the optimal 
heparin-sepharose association observed with full-length hHL. When comparing the 
heparin-sepharose associations of the hHL442-476 peptide to full-length hHL, it should be 
taken into consideration that active full-length hHL is understood to be in a head-to-tail 
homodimer conformation.73 The head-to-tail homodimer conformation contains both the 
N- and C-terminal HBDs of hHL. This might account for full-length hHL having a 
greater association to heparin-sepharose compared to the hHL442-476 peptide. In fact, the 
lower heparin-sepharose affinity is characteristic of lipase monomers. hLPL monomers 
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have been observed to have a lower affinity for heparin-sepharose compared to their full-
length dimer, with their elution being characterized from 0.6-0.75 M NaCl.97,98 
 It is not just lipase monomers that have been observed to have lower heparin-
sepharose affinities; some other species of HL also tend to have low heparin-sepharose 
affinities. When Breedveld et al. characterized the heparin binding of rat HL (rHL), they 
observed two protein peaks that eluted from heparin-sepharose, one at 0.3 M and 0.8 M 
NaCl, indicating that there are differences in the heparin binding abilities of rHL.99 
Interestingly, the NaCl molarity required for rHL is very comparable to what was 
observed for the hHL442-476 peptide.  
 Other studies that have investigated the HBDs of hHL have also observed that 
small peptides encompassing putative HBDs elute from heparin-sepharose at lower NaCl 
concentrations.74 When the peptide encompassing amino acids 304-323 of hHL was 
tested for heparin-sepharose binding ability, it was observed to elute at 0.42 M NaCl. The 
amino acids important for the association of this peptide are highlighted in the green box 
in Figure 4. Although the NaCl concentration is higher than observed for the hHL442-476 
peptide, it demonstrates that a single HBD is not sufficient to retain the association by the 
full-length dimer of hHL. 
 Additionally, the hHL442-476 peptide has an analogous heparin-sepharose 
association compared to other smaller peptides that are also enriched with arginines and 
lysines.100 Specifically, Caldwell et al. investigated the HBD of proteins using small (7-
mer) peptides that were either enriched or non-enriched with arginines and lysines.100 The 
enriched peptides were observed to have the highest heparin association, being eluted at 
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0.3 M NaCl compared to the non-enriched peptides, which were eluted with 0.15 M 
NaCl. This provides further evidence that the basic amino acids of the hHL442-476 peptide 
do contribute to its association with heparin-sepharose.  
 
4.1.2 Displacement of hHL from cell surfaces with the hHL442-476 peptide 
 
 It is unclear whether hHL is active only within the circulation or when also bound 
to HSPGs on the cell surface. It was originally thought that lipases were only active when 
bound to the cell surface and that this enhanced their catalytic activity. However, recent 
studies have concluded that lipases are catalytically inactive when bound to the cell 
surface and only become active when displaced from the cell surface.78,80 This is one 
reason why the ability of the hHL442-476 peptide to displace hHL from cell surfaces was of 
interest (Figure 11).  
The cell surface displacement studies for this thesis were conducted at 4°C. It has 
been previously shown that HEK-293T cells can be cultured at 4°C for up to nine days, 
while their cellular processes and cellular turnover dramatically slows.101 This 
temperature was chosen in order to supress cell surface turnover and to get a true 
representation of hHL displacement without the influence of any newly synthesized 
protein. Figure 11 shows that the hHL442-476 peptide does displace hHL from the cell 
surface into the media, and the hHL that was displaced by the hHL442-476 peptide was 
catalytically active. However, the hHL442-476 peptide did not displace as much hHL as 
heparin, as the amount activity was 57% lower. The lower activity and the decreased 
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amount of hHL displaced to the media by the hHL442-476 peptide could be a result of many 
factors, including the peptide concentration, incubation time, and temperature.  
The optimal amount of hHL442-476 peptide for treatment remains to be determined. 
The 200 µg/mL of the hHL442-476 peptide used may not be enough to optimally displace 
hHL from cell surfaces. It is known that hHL is displaced from cell surfaces by various 
proteins, such as HDL.80 As a comparative control, it would be interesting to test the 
displacement of hHL by the hHL442-476 peptide compared to HDL mediated displacement. 
The optimal incubation time also needs to be determined for this displacement 
assay. For this thesis, the incubation time was 1 hour. However, to get a better 
representation of the ability of the hHL442-476 peptide for displacing hHL from cell 
surfaces, various times points should be taken. Observing the amount of hHL displaced 
over time will help determine if the hHL442-476 peptide is transiently displacing hHL from 
the cell surface.  
Another parameter that needs to be optimized is the temperature. The 4°C 
temperature is good for slowing cellular turnover. However, it is not physiologically 
relevant. Once both the optimal hHL442-476 peptide concentration and incubation time are 
determined, this experiment needs to be conducted at 37°C. Optimizing this experiment at 
37°C is also important for future cholesterol efflux experiments.  
In order to make better inference about the ability of the major HBD within the 
hHL442-476 peptide, a scrambled peptide could have been employed. This would provide 
valuable information not only about the ability of the hHL442-476 peptide but also about the 
significance of the arrangement of the positively charged amino acids located within the 
	   99	  
HBD of hHL. This would serve as a more significant control than the plain DMEM media 
that was used in this experiment. A recombinantly expressed scrambled peptide would be 
ideal. However, it is possible that difficulty may arise with its purification, similar to that 
encountered with the hHL442-476 peptide.    
 
4.1.3 Displacement of hLPL from cell surfaces with hHL442-476  peptide 
 
 To determine if the hHL442-476 peptide specifically displaces hHL or if it displaces 
other cell surface associated lipases, the displacement assays were conducted with HEK-
293T cells expressing myc-tagged hLPL. Figure 12 shows the activity data from the 
HEK-293T cells expressing myc-tagged hLPL treated with the hHL442-476 peptide. From 
the activity data alone, it appears that the hHL442-476 peptide does displace hLPL-myc 
from cell surfaces. The percent of total heparin releasable hLPL-myc and hHL activity by 
the hHL442-476 peptide treatment are very similar – (36% and 43%, respectively), 
suggesting that the peptide displaces both lipases equally. However, both hLPL and hHL 
are not only associated with HSPGs on the cell surface, they can also be associated with 
the LDL receptor-related protein 1 (LRP1).102,103  The lipases have a “bridging” function 
that allows for the capture of lipoproteins and brings them within close proximity of the 
LRP1. Once close enough, LRP1 can internalize the lipoproteins in a fashion similar to 
the LDL receptor.104,105 hHL has been observed to aid in the uptake of remnant 
lipoproteins both via HSPG- and LRP-dependent pathways.106 The C-termini of both 
hLPL and hHL are believed to contain the binding site for LRP1.102,107 The putative 
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binding site within hHL is located within amino acids 378-448.108 The hHL442-476 peptide 
retains seven of these amino acids, and thus it is possible that the hHL442-476 peptide might 
displace hLPL and hHL associated with LRP1 because HEK-293T cells are known to 
express LRP1.109  
 
4.2 Structural Analysis of hHL442-476 Peptide  	  
4.2.1 Secondary structural analysis of the hHL442-476 peptide  
 
  
 Considering that the data suggest the hHL442-476 peptide does displace both hHL 
and myc-tagged hLPL, structural data could be useful, not only for identifying the HBD 
of hHL, but also for designing peptides with improved binding affinity. To obtain 
information about the secondary structure of the hHL442-476 peptide, it was first subjected 
to analysis by CD using the far-UV spectral region that includes 190-250 nm.95,110 The 
CD spectrum shown in Figure 13 (Blue) suggests that the hHL442-476 peptide is in a 
random coil in the absence of heparin. This is indicated by the minimum ellipticity 
observed at 200 nm. However, this is not an uncommon observation when analyzing the 
HBD of larger heparin binding proteins.111,112 Tyler-Cross et al. observed that when 
analyzing peptides of the heparin binding protein antithrombin III, a peptide 
encompassing a low-affinity site for heparin binding (KSSKLVSANRLFG) has a random 
coil secondary structure.112 However, when the peptide having the high-affinity site for 
heparin (KFAKLAARLYRKA) was tested,	  it did have the ability to adopt an α-helical 
secondary structure in the presence of heparin. Heparin binding-induced α-helical 
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structuring was not observed in the CD data for the hHL442-476 peptide, as its secondary 
structure remained as a random coil in the presence of heparin (Figure 13, Red). Mok et 
al. made a similar observation with the heparin binding protein amyloid precursor protein 
(APP), and peptides containing the APP HBDs.111 They tested multiple peptides and the 
addition of heparin only changed the secondary structure of one of them (APP416-447), 
which adopted a more α-helical secondary structure.111 
 While heparin did not induce a change in the secondary structure of the hHL442-476 
peptide, the secondary structure inducing agent TFE induced an α-helical secondary 
structure, with the CD minimum, which was at 200 nm, shifting and changing to become 
two minima at 210 and 220 nm (Figure 14, Black). Caution must be used when making 
inferences about the hHL442-476 peptide’s propensity to adopt a different secondary 
structure in the presence of TFE. The mode of action of TFE is unknown. However, it is 
hypothesized that TFE enhances hydrogen bond formation in the protein and/or it lowers 
the dielectric value of water to allow for electrostatic interactions to occur.113-115 
  hPL has been shown to have a two domain structure with the N-terminal region 
having an α/β structure and a central β-sheet, and the C-terminal region consisting of a β-
sandwich, made by two layers of β-sheets, with four antiparallel strands.70 hHL is thought 
to have a structure similar to hPL. However, residues 442-476 of hHL cannot be aligned 
with the C-terminal residues of hPL. Thus, the secondary structure of hPL cannot be used 
to make secondary structure inferences for the hHL442-476 peptide. However, there are 
bioinformatic tools that can predict the secondary structure of a protein based on its 
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amino acid sequence. PredictProtein was employed to elucidate secondary structure 
information about the hHL442-476 peptide.116 PredictProtein predicted that the hHL442-476 
peptide has no defined secondary structure (data not shown). Thus, further studies were 
employed to provide information about the interaction between the hHL442-476 peptide and 
its association with heparin, as it is crucial for elucidating structural information about the 
hHL442-476 peptide and thus, the C-terminal region of hHL.   
 
4.2.2 Tertiary structural analysis of the hHL442-476 peptide  
 
 After investigating the secondary structure of the hHL442-476 peptide, 1H-NMR was 
used to determine the overall structure of the hHL442-476 peptide. As seen in Figure 15A, at 
25°C the hHL442-476 peptide has few peaks within the H-N region, most likely indicating 
that the hHL442-476 peptide is switching between conformations.117 Even when the 
temperature was lowered to 5°C, the 1H-NMR spectrum did not reveal any tertiary 
configuration (Figure 15B). Based on the CD analyses, TFE induced an α-helical 
structure in the hHL442-476 peptide, but this was not duplicated in the 1H-NMR spectra 
obtained (Figure 16). Lastly, the combination of TFE and low temperature did not induce 
any observable structuring (Figure 16C). In agreement with my observation that TFE 
does not induce structural changes within the hHL442-476 peptide, Yu and Hill obtained 
similar findings when they investigated the association of peptides containing the HBDs 
of hHL with heparin.74 They observed that the (secondary structure inducer) TFE did not 
have any effect on the heparin association of the various hHL peptides tested. Thus, the 
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structural effect of TFE does not influence the association the HBDs of hHL to heparin-
sepharose.  
 To further investigate the tertiary structure of the hHL442-476 peptide, resonance 
data were collected for the hHL442-476 peptide in the presence of heparin. The spectra in 
Figure 17 show that heparin did induce the appearance of more hHL442-476 peptide peaks 
within the H-N region. The two large peaks at 7.0 and 8.0 ppm are likely heparin itself, 
due to their peak width and height. The signals are too narrow to be coming from a more 
ordered hHL442-476 peptide. Considering that heparin is a highly sulfated molecule and 
that even its molecular mass is an estimate between 12-30 kDa, the published 1H-NMR 
spectra for heparin are highly varied.118-120 This variation depends upon the source, batch, 
and if there are any impurities present with the heparin. Table 3 lists the chemical shifts 
of the peaks induced by heparin. Judging from the correlation patterns observed in the 
TOCSY and NOESY spectra, the new peaks could possibly be from the association of 
basic amino acids such as arginines and lysines with heparin.121 
 There are various other mimetic peptides that have been synthesized for the 
purpose of raising levels of preβ-HDL in the circulation. However, they are designed to 
mimic apolipoproteins rather than to mimic hHL. The tertiary structures of several 
apolipoproteins are known.23,122,123 The mimetic peptides based on apolipoproteins are 
designed to contain amphipathic α-helices that include various positively charged amino 
acids.124,125 
  The D-4F peptide, a mimetic of apoA-I, can reduce lesions in both apoE-deficient 
and LDLR-deficient mice.126 In human trials, the D-4F peptide increased the anti-
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inflammatory properties of HDL.127 However, the D-4F peptide has low bioavailability 
and no recent studies have been published.  
 Perhaps the most recent mimetic peptides being tested for combating CVD are 
mimetic peptides for apoE. These peptides also have an amphipathic α-helical 
structure.124,128 One of the peptides that showed great promise in vitro was ATI-5261, 
because it promoted preβ-HDL formation and RCT.129 However, when the peptide was 
tested in vivo, it increased muscle toxicity in wild-type C57BL/6 mice, while also 
increasing TG levels.130 These side effects were the consequence of aromatic 
phenylalanine residues on the polar face of the peptide, along with the large number of 
positively charged arginines. With this information in mind, a new non-toxic mimetic 
peptide (CS-6253) was designed.131 This peptide has the ability to form preβ-HDL-CS-
6253 particles that can accept cholesterol and deliver cholesterol to liver cells in vitro.130 
Even though these studies demonstrate the use of mimetic peptides for combating CVD, 
they do not come without their own pitfalls. These mimetic peptide therapies focus on the 
use of apolipoproteins as the vehicle for directly increasing preβ-HDL, unlike the hHL442-
476 peptide, which aims to increase hHL activity and possibly indirectly raising preβ-
HDL. Nevertheless, the in vivo information gained from the apoE studies could be 
applied to the in vivo use of the hHL442-476 peptide. Determining the structure of the 
hHL442-476 peptide is not only important for elucidating the HBD of hHL, but also for 
improving the efficacy and reducing potential toxicity of the therapeutic hHL442-476 
peptide.  
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4.3 Troubleshooting the Purification of the hHL442-76 Peptide 
 
 Although a minor portion of the results was the purification of the hHL442-476 
peptide, it still required just as much optimization as the functional assays. The 
expression of Trx fusion proteins commonly results in a high yield of functional 
protein.131 Trx fusion proteins tend to adopt their proper tertiary conformation because of 
their ability to be expressed in E. coli in a soluble form that is not trafficked into inclusion 
bodies.131 The Trx protein also provides proper disulfide bridge formation of the 
expressed protein.132,133  
 In attempts to separate the hHL442-476 peptide from Trx and thrombin, size-
exclusion chromatography was first used. In theory, the 7.9 kDa hHL442-476 peptide should 
be easily separated from the 12.1 kDa Trx protein and the 37 kDa thrombin. However, the 
unsuccessful separation could be due to overloading of the Sephacryl-100 column, which 
would result in the column becoming saturated with proteins and the proteins eluting 
together. This could also be a consequence of the saturation of nickel-sepharose in the 
step prior to the size-exclusion. Nickel-sepharose chromatography is usually sufficient to 
purify a recombinately expressed protein from all of the non-specific bacterial proteins.134 
However, when overloaded with protein, nickel-sepharose fails to achieve proper 
separation. This would leave bacterial proteins present that could be affecting the 
separation of the hHL442-476 peptide on size exclusion chromatography. To account for the 
overloading of both the nickel-sepharose and size-exclusion columns, the amount of 
bacterial culture used for protein purification was reduced. However, it did not result in 
the hHL442-476 peptide being successfully purified by size-exclusion (Figure S5). This is 
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why heparin-sepharose was then employed for isolation of the hHL442-476 peptide. When 
the hHL442-476 peptide is used for in vivo studies, the best way to optimize its purification 
would be to use fast protein liquid chromatography. This would allow the hHL442-476 
peptide to be purified in an efficient manner that would decrease the time required to 
purify large amounts of hHL442-476 peptide. This method would also cut down on the 
impurities that co-elute with the hHL442-476 peptide. If the hHL442-476 peptide can be 
purified via this method, it possibly could produce a concentrated sample that is required 
for structural analysis via NMR.  
 
4.4 Perspectives and Future Directions     
 
 The role that hHL plays in the development of atherosclerosis still remains to be 
clarified. Numerous studies suggest hHL has a pro-atherogenic function,62,65,135 while 
other studies suggest it has an anti-atherogenic function.57,58,60,61 Considering these 
conflicting studies on whether hHL is pro- or anti-atherogenic appears to vary upon the 
model system used. The controversy of whether hHL is pro- or anti-atherogenic not only 
holds true for animal models, but conflicting results also exist from human studies. Some 
of these studies suggest that high levels of active hHL correlate to higher levels of 
smaller, denser LDL particles, which are considered to be pro-atherogenic in nature.134,136 
On the other hand, there have been studies suggesting that a deficiency of hHL leads to a 
pro-atherogenic phenotype, due to an abnormally high TG content of the LDL 
particles.137,138 Subjects with a deficiency of hHL, together with genetically low levels of 
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CETP, have been observed to exhibit an increased the risk of CVD.139 In addition, 
decreased hHL activity has been associated with buoyant LDL particles and higher 
HDL2-C,140 which is considered to represent an anti-atherogenic phenotype. With all of 
this in mind, hHL is very important in lipoprotein metabolism.141-143 However, with the 
number of contradictory studies, much more needs to be clarified about its function in 
atherosclerosis. 
 The primary aim of this study was to generate a mimetic peptide for hHL with the 
goal of displacing active hHL from cell surfaces. The purpose of this aim was to generate 
a tool that could release active hHL from cell surfaces and one that might have the 
potential to generate more preβ-HDL within the circulation and improve RCT. The 
second aim was to reveal structural features of the hHL442-476 peptide to provide novel 
information about the C-terminal structure of hHL, considering the lack of knowledge 
regarding its structure. Investigating the function and structure of the hHL442-476 peptide 
has provided initial evidence that the use of mimetic peptides can displace cell surface 
associated hHL. The next step is to extensively test the hHL442-476 peptide in vivo for its 
ability to displace cell surface associated hHL to improve cholesterol efflux, RCT, and 
CVD outcomes using animal models. Perhaps the most widely used atherosclerosis 
mouse models are the apoE knockout (apoE-/-) and the LDL receptor knockout mice. The 
apoE-/- mice spontaneously develop atherosclerosis even when fed a standard chow 
diet.64 On the other hand, the LDL receptor knockout mice require dietary cholesterol to 
develop atherosclerosis.59 This is not the only difference between the two models: the 
apoE-/- mice tend to have lower circulating HDL-C compared to wild-type mice.64,144 
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Conversely, LDL receptor knockout mice tend to have slightly elevated HDL-C 
compared to wild-type mice, and a lipoprotein profile that resembles that of humans, with 
cholesterol mainly confined to the LDL fraction.59 This may be a good background model 
to study the hHL442-476 peptide on hHL displacement and RCT in vivo. To appropriately 
test the hHL442-476 peptide, the LDL receptor knockout mice must also be deficient in 
mHL but expressing hHL. This is due to the differences in the cell surface association 
between hHL and mHL. 
 The data obtained for elucidating the tertiary structure of the hHL442-476 peptide at 
best showed that the peptide adopts conformational changes in the presence of heparin. 
HL exhibits a significant association to lipid emulsions (such as Intralipid);78 however, 
the NMR studies for this thesis were conducted in aqueous environments. Thus, future 
NMR experiments could be conducted with the hHL442-476 peptide in the presence of lipid 
micelles. If future structural experiments elucidate the tertiary structure of the hHL HBD, 
both in the absence and presence of heparin, it would provide useful information that can 
be used toward designing structural modifications to the peptide that may improve hHL 
displacement and possibly lead to better CVD therapies.  
 
4.5 Overall Conclusion 
 
 This research has provided a foundation for the use of mimetic peptides for the 
displacement of lipases from cell surfaces. Through the functional analysis of the hHL442-
476 peptide, it can be concluded that it has a weak association to heparin-sepharose but it 
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exhibits the ability to displace cell surface associated lipases. The weak heparin-sepharose 
association could be a desirable property of the hHL442-476 peptide, such that it may only 
displace some (but not all) of cell surface bound lipases, thus leaving some lipase to carry 
out bridging functions and associations with LRP1. In conjunction with the structural 
analysis, it can be concluded that the hHL442-476 peptide is relatively unstructured but 
specific amino acids appear to interact with heparin. Further analysis of the structure of 
the hHL442-4476 peptide needs to be conducted in order to draw any conclusion about the 
potential tertiary structure of the major HBD of hHL.  
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Figure S1: Amino acid sequence of the hHL442-476-Trx protein 
Highlighted in black is the partial sequence of Trx with the link region highlighted in 
red. The hHL 442-476 sequence is highlighted in green. The cleavage site for thrombin 
is highlighted in purple and the enterokinase cleavage site is highlighted in light blue. 
The 6xhis tag is highlighted in blue and the S-tag is highlighted in orange.  
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Figure S2: Activity of wild-type LPL compared to myc-tagged LPL using a 
resorufin ester hydrolysis assay 
HEK-293T cells in 100-mm dishes were transfected with 6.5 µg of either wild-type 
hLPL cDNA (in pcDNA3 plasmid), myc-tagged hLPL, or pcDNA3 vector using 
Lipofectamine™. After 23.5 hours post transfection, media were replaced with 
DMEM containing 100 U/mL heparin. After 0.5 hours, media were collected and 
analyzed using a resorufin ester hydrolysis assay. n=3, technical replicates.   
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Figure S3: Immunoblot of the displacement of LPL by the hHL442-476 peptide 
using polyclonal LPL antibody 
Immunoblot of hLPL displaced from HEK-293T cells expressing myc-tagged hLPL 
with DMEM, 100 U heparin, or 200 µg/mL hHL442-476 peptide. Cells in 6-well plates 
received one of the following treatments for 1 hour at 4°C: DMEM containing 100 U 
heparin (positive control), plain DMEM (negative control), or DMEM containing 200 
µg/mL hHL442-476 peptide. Following the hour incubation, the media were collected 
and the cells were washed with ice cold plain DMEM. The media were analyzed for 
the presence of LPL by immunoblot with the polyclonal LPL (H-53) antibody. No 
immunoreactivity was observed for the expected molecular mass for hLPL (58 kDa). 
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Figure S4: Immunoblot of hLPL using the F-1 monoclonal hLPL antibody 
HEK-293T cells in 100-mm dishes were transfected with 6.5 µg of either wild-type 
hLPL cDNA in pcDNA3 plasmid or pcDNA3 vector using Lipofectamine™. After 23.5 
hours, media was replaced with DMEM containing 100 U/mL heparin. After 0.5 
hours, media and cell lysates were collected and analyzed via immunoblot analysis. No 
immunoreactivity was observed for the expected molecular mass for hLPL at 58 kDa.  
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Figure S5: Isolation of hHL442-476 peptide from Trx protein by size-exclusion 
chromatography 
Approximately 15 mL of the hHL442-476 peptide, Trx and thrombin was lyophilized and 
resuspended in 2 mL of 1X TBS (pH 7.0) and loaded onto a Sephacryl S-100 size-
exclusion column that was pre-equilibrated with 1X TBS (pH 7.0). One mL fractions 
were collected from the column and the presence of the hHL442-476 peptide was 
analyzed by SDS-PAGE using a Tris-tricine gradient gel (4-16%) stained with 
Coomassie blue. The contaminated hHL442-476 peptide was observed in fractions (F) 
50-75, denoted by *. However, the hHL442-476 peptide was not isolated to purity.  
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